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CHAPTER I 
 
INTRODUCTION 
 
Hematopoiesis 
Hematopoiesis is the process by which all types of blood cells are produced. 
Prenatally, hematopoiesis initiates in the extra-embryonic yolk sac where primitive (or 
embryonic) nucleated red blood cells are formed. At later stages of development, 
hematopoiesis shifts to the fetal liver, spleen and eventually to the bone marrow (BM). 
The other site of hematopoietic activity which functions in mouse ontogeny at the pre-
liver stage of hematopoiesis is the aorta-gonad-mesonephros (AGM) region, where 
pluripotential hematopoietic stem cells (HSCs) are formed and get sublocalized to the 
dorsal aorta. Stem cells in the AGM region appear before the fetal liver, indicating the 
importance of this mesodermal region of the embryo in stem cell migration. After birth, 
hematopoiesis is restricted to the BM and daily blood cell production amounts to 
approximately 2.5 billion red cells, 2.5 billion platelets, and 1.0 billion granulocytes per 
kilogram of body weight. In the normal physiological system, the level of different types 
of blood cells are maintained within a range by a highly self-regulatory mechanism that is 
responsive to the demands put upon it. Under abnormal conditions like BM replacement 
or during excessive demand of blood cells due to anemia, extramedullary hematopoiesis 
is initiated in the liver or spleen.  
Mature blood cells of different lineages are formed from the same primitive HSC 
in the bone marrow. The HSC in the BM has the capacity to proliferate, self-renew and 
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differentiate to lineage specific progenitor cells that further differentiate into mature cells 
that are released into the peripheral blood. Although a small percentage of this HSC 
population is cycling at any given time, daily production of 6 billion blood cells from this 
small population represents a massive amplification process. 
 
Hierarchical organization of adult hematopoiesis 
Hematopoiesis is a complex process in which a small number of HSCs expand 
and differentiate to form mature cells of different lineages that perform specific functions 
in the physiological system. Differentiation of progenitor cells into lineage specific cells 
results in loss of multi-lineage potential and follows a hierarchical pattern where HSCs in 
the BM give rise to both myeloid- and lymphoid-lineage specific cells through the 
formation of multi-potential progenitor (MPP) cells. This complex process of 
differentiation and lineage commitment is controlled by a collection of transcription 
factors, cytokines, cell adhesion molecules and external signals from the BM 
microenvironment. According to the classical model, the MPPs give rise to common 
lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs) and CLPs 
further differentiate into T cells, B cells and Natural Killer (NK) cells while CMPs 
differentiate into monocytes, granulocytes, megakaryocytes and erythrocytes (Fig. 1). 
Megakaryocytes and monocytes differentiate further into platelets and macrophages, 
respectively.   
Over the past three decades, several models other than the classical model have 
been proposed. One of these is a stochastic model postulated by Ogawa and colleagues 
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(Ogawa et al., 1983). This model is based on the observation that various combinations of 
lineages can be found in the colonies of the colony forming unit in culture (CFU-C) 
assay, leading to the proposal that the combination of lineages occurs at random during 
the lineage restriction process. Therefore, this model is also called the ‘random 
restriction’ model. This proposal was originally restricted to myelo-erythroid lineages, 
but some researchers have interpreted this model to include lymphoid lineages. 
In another model proposed by Brown and colleagues in 1985, multipotent 
progenitors were proposed to change their potential to make erythroid, myeloid, B and T 
cells, along with differentiation, and between each stage, bipotential progenitors would be 
produced (Brown et al., 1985; Brown et al., 2007). This so-called ‘sequential 
determination’ model incorporates the notion that B cells and macrophages are closely 
related, which does not explain the finding that T cell progenitros that have terminated B 
cell potential still retain myeloid potential. 
In 1996, a different model was proposed by Singh and colleagues based on 
findings in mice deficient for certain transcription factors. In this model, the erythroid 
branch from the HSC occurs first, and the resulting CMLP subsequently generates a 
myeloid progenitor and CLP (Singh, 1996). In this regard, the order of developmental 
options is similar to the sequential determination model described above. This model was 
primarily based on the following two findings: (i) in PU.1-/- mice, erythroid cells are 
formed normally but myeloid, T and B cells are defective (Scott et al., 1994); and (ii) 
Ikaros-/- mice exclusively lack T and B cells (Georgopoulos et al., 1994). However, later 
studies reported that T cell development was not so strongly affected in these cases 
(Wang et al., 1996; Spain et al., 1999). Moreover, the lack of multiple lineage cells in a 
3 
 
knockout mouse does not necessarily prove the presence of common progenitors for 
them. 
Irrespective of hematopoiesis differentiation model, a critical feature of the HSC 
is to balance between apoptosis, self-renewal and differentiation and must express genes 
that enable it to make that choice. Moreover, lineage specification requires up-regulation 
of genes associated with the adopted pathway and silencing of genes that specify the 
alternate pathways. This unique gene expression profile in the lineage-specific mature 
cells enable them to perform critical physiological functions and this whole process of 
hematopoietic cell differentiation and function is tightly regulated by the action of several 
different transcription factors and growth factors. 
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Figure 1. Formation of lineage committed mature cells from parent HSCs through 
formation of MPPs. HSCs serve as parent cells that can self-renew and also differentiate 
to form MPPs. The MPPs further diverge to form CMPs and CLPs; while CMPs form 
erythrocytes, megakaryocytes (platelets), granulocytes and monocytes, CLPs give rise to 
lymphoid lineage cells which are T-cells, B-cell and natural killer (NK) cells. 
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Monocytopoiesis 
Monocytes or macrophages act as critical effectors and regulators of innate 
immunity and inflammatory responses. These cells represent a subgroup of leukocytes or 
white blood cells (WBCs) originally described as a population of BM-derived myeloid 
cells that circulate in the blood as monocytes and populate tissues as macrophages in the 
steady state and during inflammation (van Furth and Cohn, 1968). Monocytopoiesis, or 
formation of monocytes, is a part of the myeloid differentiation system with CMPs giving 
rise to colony forming units-granulocyte/monocyte (CFU-GM) that sequentially 
differentiate into colony forming units-monocyte (CFU-M), monoblasts, promonocytes 
and finally monocytes (Fig. 2). Monocytic differentiation is driven by cytokines 
including interleukin-3 (IL-3) and macrophage colony stimulating factor (M-CSF or 
colony stimulating factor 1, CSF-1), and is dependent on expression of the CSF-1 
receptor (CSF1R, also known as C-FMS, M-CSFR and CD115), a member of the 
CSF1/PDGF receptor family of transmembrane tyrosine-protein kinases (Cecchini et al., 
1994; Dai et al., 2002; Sasmono et al., 2003). Other important monocyte-macrophage 
(MM)-specific surface proteins include Fcγ receptor (II/III), macrosialin (CD68), 
scavenger receptor (SR), F4/80, CD14, CD11b and CD18. Monocytes, once formed in 
the BM, enter the blood stream and can migrate from blood into tissues with the help of 
chemokine receptors and adhesion receptors. While peripheral blood monocytes are able 
to perform phagocytosis and cytokine secretion, these functions are further enhanced with 
its differentiation into tissue macrophages, which participates in innate and adaptive 
immunity and helps in the maintenance of tissue homeostasis. 
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Transcription factors play critical roles in monocytopoiesis. Ectopic expression of 
several transcription factors like MafB, c-Maf, Egr1, ICSBP/IRF8, KLF4, E2-2 and PU.1 
in early progenitors drives MM differentiation (Auffray et al., 2009). PU.1, an Ets-family 
member has key selective functions at several branch points of myeloid lineage 
diversification, particularly during lineage commitment towards either macrophage or 
dendritic cells (Bakri et al., 2005). Inhibitory interactions of PU.1 to repress GATA-1 and 
GATA-2 expression is required for blocking the commitment towards the 
erythroid/megakaryocytic and mast cell lineages respectively (Walsh et al., 2002). As a 
downstream target of PU.1, KLF4 can also induce macrophage fate and can selectively 
rescue monocyte differentiation of PU.1-/- progenitors, whereas KLF4 deficiency biases 
myeloid progenitor differentiation towards the granulocytic fate (Feinberg et al., 2007). 
At later differentiation stages, intermediate expression of PU.1 in GMPs can overcome 
the neutrophil fate-inducing effects of the basic leucine zipper transcription factor 
C/EBPα and activate the macrophage-specifying zinc finger transcription factors Egr-1 
and Egr-2 (Laslo et al., 2006; Auffray et al., 2009). Similarly, introduction of the 
transcription factor ICSBP/IRF-8 in ICSBP/IRF-8-deficient myeloid progenitors resulted 
in monocytic differentiation at an expense of granulocytic differentiation (Tamura et al., 
2000). These studies suggest that a balance between agonistic and antagonistic 
transcription factors that drive alternative fates is critical for monocyte differentiation.  
In summary, monocytopoiesis is a critical and complex process that is highly 
regulated by different transcription factors that can in turn couple with cytokine receptor 
signaling pathways during lineage commitment. The functional aspect of monocyte-
macrophage cells are further controlled by cell migratory stimuli from the inflammatory 
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milieu, expression of chemokine and adhesion receptors, and pathogen-associated pattern 
recognition receptors. Although studies done over the years have shed light on this 
process, transcription factors that control MM subtype-specific programs need to be 
identified. Models that closely reproduce defined differentiation stages in culture and 
development of new genetic tools of gene expression regulation could accelerate 
discovery in this area. 
 
 
 
Figure 2. Schematic representation of differentiation of HSCs towards peripheral blood 
monocytes and finally tissue macrophages. Cytokines and growth factors required are 
shown adjacent to the arrows which point towards more differentiated cell types. Cells 
become lineage restricted with differentiation and alternative lineages diverge away from 
monocyte-macrophage lineage. Monocytes are released into blood stream and reach 
tissue sites where they develop into the most mature phagocytic cells. 
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T cell Acute Leukemia 1 (TAL1) 
The TAL1 gene, also known as stem cell leukemia (Scl), encodes a class II basic 
helix-loop-helix (bHLH) transcription factor, 47 kD in size, and was first identified as 
aberrantly expressed in 3% of human T cell acute lymphoblastic leukemia (T-ALL) 
cases. This results from a t(1;14)(p34;q11) translocation, that cleaves the TAL1 gene on 
chromosome 1, separating its 5' end from the rest of the gene that is transposed into the T 
cell receptor α/δ locus on chromosome 14 (Carroll et al., 1990). In another 12-26% of T-
ALL cases, interstitial deletion of approximately 90-100 kb region of chromosome 1 puts 
the promoter region of an upstream gene, SCL interrupting locus (SIL) in direct contact 
with the coding region of TAL1 (Aplan et al., 1990; Brown et al., 1990; Bernard et al., 
1991). Taken together, gain-of-function mutations in TAL1 contribute to approximately 
30% of T-ALL cases. 
TAL1 recognizes E box sequences (CANNTG) in gene regulatory regions in 
DNA, and binds these sequences as a heterodimer with class I bHLH transcription factors 
termed E proteins (Hsu et al., 1991; Doyle et al., 1994; Hsu et al., 1994b). E proteins that 
interact with TAL1 are either products of the E2A gene, E12 and E47, or related protein 
E2-2 or HEB/HTF4 gene products. Interaction of TAL1 with other factors is mediated by 
its HLH domain and sequence-specific DNA binding is mediated by its basic region. The 
preferred sequence that is recognized by this heterodimer is CAGATG with further 
preferences on either side of the E box governed by the associated interacting E protein 
(Hsu et al., 1994a). In erythroid cells, a larger multimeric protein complex consisting of 
TAL1, E2A, LMO2, GATA-1 and Ldb1 binds to a different E box (CAGGTG) combined 
with a GATA site separated by 9-12 bp (Wadman et al., 1997). In CD4-CD8- thymocytes 
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from Lmo2 transgenic mice, instead of an E box-GATA motif, two different E boxes 
(CATCTG and CAGRTG), spaced approximately 10 bp apart, were found to be occupied 
by two Tal1-E protein heterodimers bridged together by a pair of LMO1/2 and Ldb1 
molecules (Grutz et al., 1998). 
 
Transcriptional Regulation by TAL1 
TAL1 regulates transcription of target genes by forming a heterodimer with E 
protein binding partner and results in maximum transcriptional activation in erythroid 
cells in association with zinc finger GATA transcription factor family and LMO2 and 
Ldb1 (Wadman et al., 1997). This correlated with formation of two high molecular 
weight protein-DNA complexes in gel-shift assay. CAT reporter assays done in T cells 
showed transactivation of a minimal thymidine kinase promoter linked to four copies of 
preferred E box sites by TAL1, either LMO1 or LMO2 and also GATA-3, despite the 
absence of a GATA-binding site (Ono et al., 1997). In T cell-specific transcriptional 
activation of the retinaldehyde dehydrogenase 2 (RALDH2) gene, TAL1 and LMO1/2 
can act as cofactors to GATA3 that binds a single GATA site in a cryptic promoter that is 
indispensable for RALDH2 expression (Ono et al., 1998). In this situation, direct DNA-
binding ability of TAL1 is not required to regulate transcription of a target gene. In 
murine erythroleukemia (MEL) cells, the multimeric protein complex consisting of 
TAL1, E47, LMO2, Ldb1, SSBP2  and GATA-1, transactivates Protein 4.2 (P4.2) 
expression by directly binding two E box-GATA motifs in its promoter region (Xu et al., 
2003; Xu et al., 2007). A similar complex comprised of TAL1, E47, LMO2, Ldb1 and 
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GATA-1, also activated the Glycophorin A promoter in a human bipotent cell line TF-1 
(Lahlil et al., 2004). 
In addition to its function as a transcriptional activator, TAL1 can also act as a 
transcriptional repressor. It repressed transcription from artificial promoters containing 
preferred E box sequences (CAGATG) (Hsu et al., 1994a), E boxes from the µE2 and 
κE2/µE5 immunoglobulin enhancers (Doyle et al., 1994; Voronova and Lee, 1994; 
Hofmann and Cole, 1996), and also a MyoD binding site (Goldfarb and Lewandowska, 
1995; Hofmann and Cole, 1996). LMO1 also increased TAL1 mediated repression of 
immunoglobulin µE5, µE2 and µE3 E boxes (Chervinsky et al., 1999) and LMO1 and 
LMO2 potentiated TAL1-mediated repression of the CD4 proximal enhancer and 
enforced expression of TAL1 and LMO1 inhibited T cell differentiation (Herblot et al., 
2000). Moreover, TAL1 interacted with the nuclear co-repressor mSin3A and histone 
deacetylase 1 (HDAC1), both in vitro and in vivo, to repress transcription of an E box-
containing promoter and a GAL4 reporter linked to a thymidine kinase minimal promoter 
(Huang and Brandt, 2000). This repression was relieved by the action of a specific 
histone deacetylase inhibitor trichostatin A (TSA), suggesting that this TAL1-corepressor 
complex inhibits gene expression. The SWI/SNF protein Brg1 was associated with the 
TAL1-containing protein complex at P4.2 promoter region in uninduced MEL cells and 
the association decreases with terminal erythroid differentiation and increased P4.2 
expression (Xu et al., 2006). Lastly, the transcriptional co-repressor ETO-2 interacts with 
TAL1 along with another repressor, Gfi-1b, in early stages of erythroid differentiation 
and this association is lost during erythroid differentiation (Schuh et al., 2005; Cai et al., 
2009). 
11 
 
Function of Tal1 in embryonic development 
During mouse embryonic development, Tal1 expression can be detected in 
embryonic and extraembryonic mesoderm at embryonic day 7.5 post coitum (pc), 
followed by endothelial and hematopoietic cells of yolk sac blood islands at day 8.5 pc, 
and neural tube and fetal liver at day 9-10.5 pc (Kallianpur et al., 1994). The TAL1 gene 
is also expressed during early stages of human embryogenesis in aorta associated CD34+ 
hematopoietic cells and at later stages in hematopoietic progenitors in fetal liver and bone 
marrow (Labastie et al., 1998). In zebrafish embryos, Tal1 is expressed in early 
hematopoietic and endothelial progenitor cells and also at definitive hematopoiesis 
initiation sites (Gering et al., 1998; Zhang and Rodaway, 2007). Gene knockout studies in 
mice have identified critical functions performed by TAL1 during embryonic 
development. Tal1-/- mouse embryos lack yolk sac erythropoiesis and failed to produce 
hematopoietic progenitor cells in general, which lead to embryonic lethality at day 9.5 pc 
(Robb et al., 1995; Shivdasani et al., 1995). Embryoid bodies derived from Tal1-/- 
embryonic stem (ES) cells fail to generate hematopoietic colonies of any type (Porcher et 
al., 1996) and did not express genes encoding key hematopoietic transcription factors like 
GATA-1, PU.1, EKLF and also lacked globin and myeloperoxidase mRNA expression 
(Robb et al., 1996; Elefanty et al., 1997). Chimeric mice generated by injecting Tal1-/- ES 
cells into both wild-type and RAG2-/- blastocysts showed no contribution by Tal1-/- ES 
cells to any hematopoietic lineage (Porcher et al., 1996). Apart from its role in 
hematopoiesis, TAL1 expression in embryonic endothelium is critical for angiogenic 
remodeling (Visvader et al., 1998) and is essential for driving GATA2 expression by 
binding an intronic enhancer element (Khandekar et al., 2007). 
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Function of Tal1 in postnatal development 
In the adult hematopoietic system, TAL1 is expressed in HSCs and multipotent 
progenitors, including murine erythroid, megakaryocytic, myeloid and mast cell lineages 
(Visvader et al., 1991; Quesenberry et al., 1996; Begley and Green, 1999). Knockout of 
Tal1 at the HSC stage adversely affected erythropoiesis and megakaryopoiesis leading to 
complete loss of blast forming unit-erythroid (BFU-E) and reduced colony forming cell-
megakaryocytes (CFC-Mk) (Hall et al., 2003; Mikkola et al., 2003). In contrast, enforced 
expression of TAL1 in human CD34+ cells resulted in increased numbers of erythroid 
and megakaryocytic progenitors (BFU-E and CFC-Mk) and an increase in the size of 
erythroid colonies (Elwood et al., 1998; Valtieri et al., 1998). A LacZ reporter gene 
‘knocked-in’ to the TAL1 coding region revealed TAL1 promoter activity in progenitors 
of the erythroid lineage, B- and T-cell lineage, myeloid lineage and in multipotent 
progenitor cells capable of forming spleen colonies in irradiated mice (CFU-S12) 
(Elefanty et al., 1998).  
During in vitro differentiation of CD34+lin- human cord blood cells towards the 
erythroid lineage, TAL1 is abundantly expressed in early erythroid progenitor cells 
(Ziegler et al., 1999) with levels peaking at the CFU-E stage (Condorelli et al., 1995) but 
decreasing with terminal erythroid differentiation (Cheng et al., 1996). In the murine 
erythroleukemia (MEL) cell line, Tal1 protein expression increases with terminal 
erythroid differentiation, and a Tal1-containing protein complex activated Protein 4.2 
(P4.2) gene expression by binding its proximal promoter region (Xu et al., 2003; Xu et 
al., 2007). A similar complex was also found to regulate Glycophorin A (GPA) gene 
expression by binding to the GPA promoter region in human bipotent TF-1 cell line 
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(Lahlil et al., 2004). Other potential TAL1 targets in this lineage include genes encoding 
for transcription factors GATA-1 (Vyas et al., 1999) and EKLF (Anderson et al., 2000). 
Although conditional gene knockout studies in adult mice have shown that Tal1-null 
mice develop anemia and Tal1 is required for normal erythropoiesis, it is not essential for 
adult erythropoiesis and does not significantly impair the ability of mice to respond to 
hemolytic stress (Hall et al., 2005). 
Knockout studies done on mice have also identified a critical role of Tal1 in 
megakaryopoiesis and Tal1-null mice exhibit impaired platelet production along with 
megakaryocytic ultrastructural defects (McCormack et al., 2006). Gene expression 
analysis identified two target genes of Tal1 that encode for transcription factors NF-E2 
and Mef2C, and in megakaryoblastic cell lines, bound the promoter regions of both the 
genes (McCormack et al., 2006; Gekas et al., 2009).  
TAL1 is also expressed in mature mast cells and is required for proper 
differentiation of mast-cell progenitor cells (MCP) from the megakaryocyte-erythrocyte 
restricted cell fraction (Salmon et al., 2007). MCPs lacking Tal1 gene showed increased 
expression of Gata2 and reduced expression of IgE receptor and mast-cell proteases, 
MCP5 and MCP6 (Salmon et al., 2007). 
TAL1 expression was also detected during adult vasculogenesis in mouse models 
of both physiological and pathological blood vessel and lymph vessel formation (Tang et 
al., 2006). Knockdown of TAL1 in human primary endothelial cells repressed in vitro 
tubulomorphogenesis by reduction in vascular endothelial (VE)-cadherin gene 
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expression and an E box-GATA sequence in the VE-cadherin promoter region was found 
to be bound by TAL1, E47, LMO2 and GATA2 (Deleuze et al., 2007). 
 
Function of Tal1 in monocytopoiesis 
Although an important role for TAL1 has been demonstrated in other 
hematopoietic lineages, a function in mononuclear phagocyte production, while 
suggested by a number of observations, had not been determined. First, the mouse Tal1 
cDNA was cloned from a BM macrophage cDNA library using oligonucleotides derived 
from human HLH sequences (Begley et al., 1991). TAL1 interacts with specific E 
proteins to form productive DNA-binding complexes in the M1 monocytic leukemia cell 
line (Voronova and Lee, 1994). Although studies with this cell line and the human 
bipotent cell line TF-1 suggested that it was down-regulated during monocytic 
differentiation (Tanigawa et al., 1993; Voronova and Lee, 1994; Hoang et al., 1996), 
TAL1 mRNA or protein has been detected in mouse peripheral blood mononuclear cells 
and BM macrophages (Kallianpur et al., 1994), and zebrafish (Zhang and Rodaway, 
2007) and human (Pulford et al., 1995) macrophages. While deletion of Tal1 in adult 
HSCs did not affect granulocyte-macrophage (GM) or macrophage progenitor cells 
numbers (Hall et al., 2003; Mikkola et al., 2003), double knockout of genes encoding 
bHLH transcription factors Lyl1 and Tal1 resulted in a ten-fold reduction of myeloid 
colonies formed from lin-c-kit+Sca-1+ (LKS) cells cultured in vitro (Souroullas et al., 
2009). Moreover, 5-fluorouracil (5-FU) treatment of Tal1-/- mice resulted in a small but 
significant delay in recovery of circulating monocytes (personal communication, Dr. 
David Curtis, The Royal Melbourne Hospital, Australia). Finally, knockdown of TAL1 in 
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human cord blood CD34+ cells by short hairpin RNA (shRNA) reduced the numbers of 
both erythroid and myeloid cell progenitors (Brunet de la Grange et al., 2006).  
 
Aims of Dissertation 
The aims of this dissertation were: 
1) To evaluate Tal1 gene expression during murine monocytopoiesis.  
The first aim was to critically study Tal1 gene expression during differentiation of 
monocytes towards macrophages. TAL1 expression was detected in both mouse and 
human tissue macrophages, but a more detailed study was needed. To that end, TAL1 
expression was determined at successive stages of monocytopoiesis from CMP cells to 
monoblasts, promonocytes, macrophages and finally in activated macrophages. CMP 
cells from mouse BM were isolated using a previously described procedure (Tagoh et al., 
2002) and induced to differentiate towards macrophages by an in vitro culture system. 
Verification of this macrophage differentiation system was first carried out by 
morphological, immunocytometric and gene expression analysis of cells in the culture 
system. 
2) To study phenotypic consequences of Tal1 gene manipulation in mouse 
BM monocyte-macrophage (MM) precursor cells. 
The second aim of the study was to define the biological role of Tal1 in this 
lineage by both over-expressing and knocking out Tal1 gene expression in MM precursor 
cells. A previously established protocol of isolating monoblasts and promonocytes from 
mouse BM was utilized and the effects of Tal1 gene manipulation was analyzed in an ex 
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vivo culture system. This approach not only enabled analysis of the role of Tal1 in a 
relatively pure population of BM cells but also facilitated efficient gene knockout using 
the Cre-Lox system. In the absence of a promoter that could drive Cre expression in a 
cell- and stage-specific manner that could have enabled in vivo gene knockout, Cre was 
delivered retrovirally in MM precursor cells harboring loxP sequences flanking Tal1 
locus and the same vector was used to over-express Tal1 in wild-type (WT) cells. 
3) To identify Tal1 target genes and potential binding sites for Tal1 in 
regulatory regions of those genes. 
 
The final objective was to complement the phenotype analysis in Tal1 knockout 
and over-expressing cells with gene expression analysis. The genes that are altered in 
expression could be direct or indirect targets of Tal1 and may explain the phenotypic 
changes seen with altered levels of Tal1 expression. Genes that are affected may have 
binding sites for Tal1 in their regulatory regions and we aimed at identifying those sites 
by molecular assays in both primary BM cells and a myeloid leukemia cell line. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell lines and cell culture reagents 
The connective tissue cell line L-929, mouse myeloid leukemia cell line M1, 
mouse fibroblast cell line NIH3T3, and retroviral packaging cell line BOSC23 were 
purchased from the American Type Culture Collection (ATCC, Manassas, VA). L-929 
cells were cultured in Eagle’s Minimum Essential Medium (MEM) (Invitrogen), 15% 
FBS, 2 mM L-glutamine (Invitrogen), 1 mM sodium pyruvate (Fisher Scientific, 
Pittsburgh, PA) and 1% penicillin-streptomycin. M1 cells were maintained in RPMI 1640 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen) and 1% penicillin-streptomycin (Invitrogen) and their differentiation induced 
with 50 ng/ml of mouse interleukin-6 (mIL-6) (Stem Cell Technologies, Vancouver, 
Canada). The NIH3T3 cells were cultured in Dulbecco’s Minimum Essential Medium 
(DMEM) (Invitrogen), 10% FBS, and 1% penicillin-streptomycin. The BOSC23 cell line 
was maintained in DMEM, 10% FBS, 1% penicillin-streptomycin, and GPT selection 
medium (Millipore, Billerica, MA).  
L-cell conditioned media was used as a source of M-CSF during culture of mouse 
MM precursors. For preparation of L-cell conditioned medium, L-929 cells were seeded 
at 1.25 × 105 cells in 30 ml of medium. Media was harvested after 1-1.5 weeks and 
centrifuged at 1500 × g for 20 min and then forced through a 40 µm filter to remove 
cellular debris.  
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Retroviral expression vectors and cDNAs 
Murine stem cell virus (MSCV)-based bicistronic vectors MSCV-IRES-GFP, 
MSCV-IRES-GFP-Tal1, and MSCV-IRES-GFP-Tal1T192P have been previously 
described (Persons et al., 1997; Huang et al., 2000). A Gata2 cDNA was provided by Dr. 
J. Douglas Engel (University of Michigan, Ann Arbor, MI) and the Cre coding sequence 
was obtained from Dr. Lishan Su (University of North Carolina, Chapel Hill, NC). The 
MSCV-IRES-YFP vector was provided by Dr. Derek Persons (St. Jude Children’s 
Research Hospital, Memphis, TN) and Tal1, Gata2 or Tal1T192P cDNA was subcloned 
into this vector using EcoRI and XhoI restriction sites. 
 
Mice, genotyping and Tal1 gene knockout in MM precursor cells 
Wild-type 3 week-old C57BL/6J mice were purchased from Jackson Labs (Bar 
Harbor, ME). Mice with a loxP-targeted Tal1 allele (SCLloxP/loxP) and SCLLacZ/WT mice, 
both in a C57BL/6 background, have been previously described (Elefanty et al., 1998; 
Hall et al., 2003). The SCLloxP/loxP mice have loxP sequences flanking a 5' non-coding 
region of exon VI and the 3' UTR of the Tal1 gene. The SCLLacZ/WT mice have a LacZ 
‘knock-in’ cassette replacing exons IV, V and part of exon VI of Tal1 gene locus, hence 
rendering that allele inactive while the other allele is wild-type. All mice were housed in 
an AAALAC accredited animal facility at Vanderbilt University Medical Center 
according to approved guidelines. SCLloxP/loxP and SCLLacZ/WT mice were intercrossed to 
generate SCLloxP/LacZ mice, which were genotyped by PCR analysis of DNA extracted 
from tail biopsies. The forward primer for the floxed and wild-type Tal1 alleles was 
TCCCAAGCCCAAAGATTTCCCCAATG and for the excised allele was 
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GCAAGCTGGATGGATCAACATGGACCT. The reverse primer for all three alleles 
was GCAAGCTGGATGGATCAACATGCACCT. For detection of the Tal1 LacZ 
knock-in allele, the forward and reverse primer sequences were respectively, 
GGATGGCGGGGCACACGAGGTAA and TGCCAGTTTGAGGGGACGACGACA. 
BM cells extracted from SCLloxP/LacZ mice were transduced with either MSCV-GFP-Cre 
or its parental vector using the methods described below. Cre expression resulted in 
excision of the single floxed Tal1 locus, generating SCL∆/LacZ cells that were effectively 
Tal1 nullizygous, while compound heterozygous cells (SCLloxP/LacZ genotype) transduced 
with the parental vector served as a control. GFP-expressing cells were isolated in a 
fluorescence-activated cell sorter and returned to culture for subsequent studies. 
 
Fluorescence-activated cell sorting (FACS) and Flow Cytometry analysis 
Retrovirally transduced cells were resuspended at a concentration of 5 × 106 
cells/ml in phosphate-buffered saline (PBS) and filtered through a 70 µm filter to remove 
aggregates and debris in the suspension. These cells were sorted in a FacsAria instrument 
(Becton Dickinson, Franklin Lakes, NJ) using FacsDiva software on the basis of green 
fluorescence protein (GFP), yellow fluorescence protein (YFP), or combined GFP and 
YFP fluorescence by comparison with mock-transfected cells. After sorting, cells were 
collected in complete culture media as described below. 
Standard flow cytometry analysis was carried out in BD FacsCanto II instrument 
(Becton Dickinson), also running FacsDiva software and data analysis was carried out 
using WinList software and PKH26 dye dilution data were modeled with ModFit LT 
software (Verity Software House, Topsham, ME). 
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Isolation and culture of common myeloid precursors (CMPs) from mouse BM 
Purification and culture of CMPs were carried out according to previously 
published procedures (Tagoh et al., 2002) with certain modifications. BM cells were 
isolated from 3-5 week-old C57BL/6J mice (Jackson Labs) and depleted of lineage-
committed cells using a Mouse Lineage Cell Depletion kit (Miltenyi Biotec, Auburn, CA) 
according to the manufacturer’s recommendations. Using this kit, lineage-positive cells 
were indirectly magnetically labeled using a cocktail of biotin-conjugated monoclonal 
antibodies, as primary labeling reagent and anti-biotin monoclonal antibodies conjugated 
to magnetic microbeads as secondary labeling reagent. The magnetically labeled lineage 
positive cells were depleted by passing through a magnetic field in LS column (included 
in the kit). Unlabeled, lineage marker-negative cells, that pass through the column, were 
washed with buffer (PBS containing 1% FBS) and incubated with anti-mouse 
CD16/CD32 Fc blocker (BD Biosciences, San Jose, California) for 5 min on ice. The 
cells were then stained with Pacific-Blue-conjugated anti-mouse CD117 (c-kit) 
(Biolegend, San Diego, CA), phycoerythrin (PE)-conjugated anti-Ly6C (Miltenyi Biotec) 
and allophycocyanin (APC)-conjugated anti-CD31 (eBioscience, San Diego, CA) 
monoclonal antibodies (mAbs) or their isotype controls. The c-kithigh/CD-31high/Ly6Cneg 
population was then isolated by FACS and placed in culture containing DMEM, 15% 
FBS, 0.5 µM β-mercaptopethanol (Sigma-Aldrich, St. Louis, MO), 20 ng/ml recombinant 
mM-CSF, 15 ng/ml interleukin-3 (IL-3), and 100 U/ml interleukin-1-alpha (IL-1α)  (all 
from Stem Cell Technologies) to induce macrophage differentiation. Macrophages were 
activated by addition of 150 U/ml interferon-γ (IFN−γ) (BioLegend) and 100 ng/ml 
lipopolysaccharide (LPS) (Sigma-Aldrich). 
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Retrovirus preparation 
BOSC23 retrovirus-packaging cells (Pear et al., 1993) were transfected with 
MSCV-based vectors, using Lipofectamine 2000 (Invitrogen) following manufacturer 
recommended conditions with certain modifications. Briefly, 24 hr before transfection, 2 
× 106 BOSC23 cells were suspended in 4 ml of antibiotic-free media and plated in 60-
mm culture dishes. For transfection of each plate, 20 µl of Lipofectamine 2000 was 
mixed with 0.5 ml of Opti-MEM (Invitrogen), incubated for 5 min at room-temperature 
(RT), and mixed with another 0.5 ml of Opti-MEM containing 8 µg of DNA. The DNA-
Lipofectamine 2000 mixture was incubated for an additional 20 min at RT and added to 
the cells on the plate. Subsequently, after 3-4 hr incubation at 37˚C, old media was 
replaced with 3.5 ml of fresh antibiotic-containing media and returned to culture for 48 
hr. High-titer, ecotropic virus-containing conditioned medium was collected 48 hr after 
transfection, filtered through 0.45 µm filter and stored at -80˚C for later use. 
 
Retroviral transduction of MM precursor cells 
BM cells were isolated from 3-5 week-old mice and placed into culture in DMEM 
containing 15% FBS, 0.5 µM β-mercaptopethanol, 20 ng/ml recombinant mM-CSF, and 
15 ng/ml IL-3. After 24 hr, non-adherent cells were subjected to Pronase digestion 
(Roche, Branford, CT) followed by centrifugation over a step gradient of horse serum 
(Hyclone, Logan, UT) (Tushinski et al., 1982; Guilbert and Stanley, 1986; Stanley, 
1990). The mononuclear cells isolated were mixed with conditioned media containing 
viral particles and 4 µg/ml polybrene (Sigma-Aldrich) and subjected to two rounds of 
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centrifuge-assisted infection (9000 × g for 1 hr each at 37˚C) at an interval of 3-4 hr. 
Cells were returned to culture overnight and transduced a final time 12 hr later. After 
another 24 hr in culture, non-adherent cells were collected and analyzed for integration of 
the retroviral vector on the basis of GFP or YFP expression, and expressing cells were 
isolated and returned to culture in the presence of 20 ng/ml mM-CSF and 40% L-cell 
conditioned media. 
 
Gene expression analysis by quantitative real-time PCR 
Total cellular RNA was extracted using an RNeasy kit (Qiagen, Valencia, CA) 
and genomic DNA removed by the DNA-Free kit (Ambion, Austin, TX). RNA was 
reverse-transcribed using iScript (Bio-Rad, Hercules, CA) and specific transcripts 
analyzed by real-time PCR using iQ SYBR Green Supermix (Bio-Rad). Gene expression 
was normalized to ribosomal protein S16 (RPS16) RNA expression. The sequences of the 
primers used were: Tal1 forward primer, ATAGCCTTAGCCAGCCGCTC, Tal1 reverse 
primer, GCCGCACTACTTTGGTGTGA, RPS16 forward primer, 
CACTGCAAACGGGGAAATGG, RPS16 reverse primer, 
CACCAGCAAATCGCTCCTTG, Gata2 forward primer, 
CCGACGAGGTGGATGTCTTC, Gata2 reverse primer, 
TGGGCTGTGCAACAAGTGTG, p16(Ink4a) forward primer, 
GGACATCAAGACATCGTGCGA, p16(Ink4a) reverse primer, 
ATTGGCCGCGAAGTTCCA, m-Lys forward primer, 
CTCTGGGACTCCTCCTGCTTT, m-Lys reverse primer, 
GCTAAACACACCCAGTCGGC, Csf1r forward primer, 
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CTAGCAAGCTGGTGCGGATT, Csf1r reverse primer, 
AGCGTTGAGACTGAGAGCCC, Pu.1 forward primer, 
CGGATGTGCTTCCCTTATCAAAC, Pu.1 reverse primer, 
GGCGAATCTTTTTCTTGCTGC, iNOS forward primer 
CCAAGATGGCCTGGAGGAAT, iNOS reverse primer 
CCTGATGTTGCCATTGTTGGT. 
 
Microarray analysis 
BM MM precursor cells from wild-type mice were retrovirally transduced with 
either the MSCV-GFP-Tal1 vector or empty vector following the procedure described 
above, and GFP-expressing cells were sorted using FACS and put into culture as 
described above. Cells were cultured for 8 days and total cellular RNA was extracted 
using RNeasy kit (Qiagen) and genomic DNA removed by the DNA-Free kit (Ambion). 
Samples were submitted to the Vanderbilt Functional Genomics Shared Resource where 
quality control assays were carried out and cDNA was synthesized using 96-well 
Affymetrix one-cycle reactions (Affymetrix, Santa Clara, CA). The resultant cDNAs 
were then purified, and used as a template for subsequent in vitro transcription (IVT) 
reaction for complementary RNA (cRNA) amplification, labeled and hybridized onto 
GeneChip® Mouse 430 2.0 arrays (Affymetrix). Signal from empty vector transduced 
cells were used as baseline and genes that changed more than or equal to two-fold in Tal1 
transduced cells were analyzed for pathway analysis using Ingenuity Pathway Analysis 
software (Redwood City, CA). 
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Apoptosis analysis 
MM precursors from different times in culture were stained with APC-conjugated 
Annexin V (BD Biosciences) and the DNA-intercalating dye 7-aminoactinomycin D (7-
AAD) (Invitrogen) and analyzed by flow cytometry. Cells that excluded all stains were 
scored as viable. Briefly, the cells were suspended in 100 µl of binding buffer (10 mM 
Hepes buffer, pH 7.4, 140 mM sodium chloride, 2.5 mM calcium chloride), and pulsed 
for 15 min at room temperature in the dark with 5 µl of APC-Annexin V. After washing, 
each sample was resuspended in 500 µl of binding buffer, stained with 2 µg of 7-AAD, 
and analyzed by flow cytometry. 
 
Cell division analysis by dye-dilution method 
Cell division was analyzed with the membrane-intercalating red fluorescent dye 
PKH26 using the PKH26 MINI kit (Sigma-Aldrich). Retrovirally transduced cells were 
labeled with PKH26 according to the manufacturer’s instructions, and cells positive for 
both PKH26 and GFP fluorescence were sorted and returned to culture. Cells stained with 
a single color (GFP or PKH26) were used for comparison. Cells in culture were analyzed 
at intervals by flow cytometry and the decrease in intensity of fluorescence over time in 
culture was used to quantify cell division. This was modeled using ModFit LT software. 
 
Differentiation analysis of MM precursor cells 
Differentiation of MM precursors was studied by flow cytometry analysis of cell 
surface antigens with PE-conjugated anti-Ly-6C (Miltenyi Biotec), APC-conjugated anti-
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CD31 (eBioscience) mAbs and their isotype controls (Tagoh et al., 2002). Briefly, cells 
in culture were collected by centrifugation, washed with buffer (PBS with 1% FBS) and 
blocked for 5 min on ice with anti-mouse CD16/CD32 Fc blocker (BD Biosciences). 
Cells were then stained for 30 min with PE-Ly6C and APC-CD31 antibodies or isotype 
controls, washed, stained with 2 µg of 7-AAD and then analyzed by flow cytometry. Cell 
morphology was determined from Wright-Giemsa staining of cytospin preparations. 
 
Cell cycle analysis 
Bromodeoxyuridine (BrdU) pulse chase analysis was carried out using an APC 
BrdU Flow Kit (BD Biosciences) according to the manufacturer’s recommendations. 
Cells were labeled with 10 µM BrdU for 45 min, washed with complete media and 
returned to culture containing fresh medium. Cells were collected at specific time points 
(0, 1, 2, and 4 hr), washed with staining buffer (1× Dulbecco’s PBS, 3% FBS and 0.09% 
sodium azide), fixed in BD Cytofix/Cytoperm buffer (included in kit), and processed for 
flow cytometry analysis. Cells were also incubated with 10 µM BrdU for prolonged 
periods (12, 24, 36, and 48 hr). After labeling, these cells were processed for flow 
cytometry analysis exactly as above. 
Flow cytometry analysis of DNA staining by Hoechst 33342 (Invitrogen) and 
RNA staining by Pyronin Y (Sigma-Aldrich) was used to differentiate cells in G0 from 
those in G1. In brief, 10 µg/ml of Hoechst 33342 was added to the cells and incubated for 
45 min at 37˚C, after which cells were collected by centrifugation and fixed overnight at 
4˚C in 5% paraformaldehyde (PFA, Electron Microscopy Sciences, Hatfield, PA). Then 
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next day, cells were stained with 2 µg/ml of Pyronin Y for 30 min on ice and finally 
resuspended in 5% PFA for flow cytometry analysis. 
 
Chromatin Immunoprecipitation (ChIP) analysis 
ChIP analysis was carried out using a commercial kit (Millipore) with certain 
modifications as described (Xu et al., 2003). Formaldehyde was added to 2 × 107 primary 
mouse BM cells at a final concentration of 1% for 20 min at 37˚C. For M1 cells, cross-
linking was carried out with 1 × 108 cells that had been cultured in the presence or 
absence of recombinant mIL-6 for 48 hr. All subsequent steps were carried out according 
to the manufacturer’s instructions. The antibodies used for immunoprecipitation of 
chromatin fragments included rabbit polyclonal anti-Tal1 (Kallianpur et al., 1994), anti-
E47 (sc-763X, Santa Cruz), and anti-E2A (Yae) (sc-416X, Santa Cruz), as well as normal 
rabbit IgG (sc-2027, Santa Cruz). Immunoprecipitated DNA was analyzed by real-time 
PCR using iQ SYBR Green Supermix (Bio-Rad) and occupancy was quantified for all 
antibodies, including IgG, and expressed as percentage of input. The sequences of 
primers used were as follows: p16(Ink4a) -13 region forward, 
CCACTGGTCACACGACTG; p16(Ink4a) -13 region reverse,  
GCACGTCATGCACACG; p16(Ink4a) -2592 region forward, 
CCCTAGCCAAATCTGACAT; p16(Ink4a) -2592 region reverse, 
TCCAGGTAGTACATGCTTTCA; p16(Ink4a) -4638 region forward, 
CCTCTCCAGGGTAGTCATGG; p16(Ink4a) -4638 region reverse,  
GATGCAAGAATCACACAAAGG; p16(Ink4a) -5106 region forward, 
CACTTTGCTTATACTGGATGG; p16(Ink4a) -5106 region reverse, 
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CCAGTGAAACCCTTGTATCTT; p16(Ink4a) -6932 region forward,  
GCTTTCACAGGACACAGAAGG; p16(Ink4a) -6932 region reverse,  
TTACTCTTTCCCACCATGACC; p16(Ink4a) 3´ UTR forward, 
GGAGGGAGCAGAAGGAGG; p16(Ink4a) 3´ UTR reverse, 
ACAATCCAGCCATTATTCCC; Gata2 intron 4 forward, 
CCTGCCGGAGTTTCCTATCC; Gata2 intron 4 reverse, 
ACTGAGTCGAGGTGGCTCTGA; Gata2 3´ UTR forward, 
TCGATTCTGTGTGTGGTGGT; and Gata2 3´ UTR reverse 
ACTTCCGGTTAGGGTGCTCT. 
 
Western Blot analysis 
Western blot analysis was used to test Cre expression by MSCV-GFP-Cre vector 
and to test Tal1 expression in MM precursor cells isolated from wild-type BM. NIH3T3 
cells were transfected with the MSCV-GFP-Cre vector or MSCV-GFP parental vector 
using Lipofectamine 2000 following manufacturer’s recommendations, cultured for 48 
hr, and followed by immunoblot analysis as described later. Whole cell lysates were also 
prepared from MM precursors at days 1, 4, 6 and 8 of culture. For preparation of whole 
cell lysate, cells were washed three times with ice-cold PBS and solubilized for 30 min in 
ice-cold RIPA buffer (Millipore) containing protease inhibitor cocktail (Roche). Cells 
were lysed by passing through a 23G needle, rotated end-to-end for 30 min at 4˚C and 
then centrifuged for 10 min to pellet insoluble material. The protein concentration of 
cleared lysates was quantified using the BCA reagent (Pierce). 
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Lysate proteins were separated electrophoretically using 10% Bis-Tris NuPAGE 
gels (Invitrogen) and transferred to 0.45 µm pore nitrocellulose membranes (BioRad). 
Membranes were blocked for 1 hr in 5% non-fat dry milk at RT and then incubated 
overnight with primary antibodies to either Tal1 (sc-12982, Santa Cruz) or β-actin 
(ab8226, Abcam, Cambridge, MA) or Cre (ab24607, Abcam) at 4˚C. Membranes were 
then incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hr at 
RT and proteins were visualized by enhanced chemiluminescence using the SuperSignal 
West Pico system (Pierce). 
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CHAPTER III 
 
TAL1 EXPRESSION IN BM PRECURSORS DIFFERENTIATING TOWARDS 
MACROPHAGES 
 
Introduction 
Expression and specific functions of Tal1 have been extensively studied in 
hematopoietic lineages like erythrocytes, megakaryocytes, mast cell precursors and also 
in endothelial cells during vasculogenesis and lymphangiogenesis (Visvader et al., 1991; 
Quesenberry et al., 1996; Begley and Green, 1999). However, a detailed study of Tal1 
expression during monocytopoiesis was needed, in part because studies in the TF-1 and 
M1 cell lines suggested Tal1 expression was down-regulated with differentiation. 
However, both these leukemic cell lines constitute artificial models in which 
differentiation is induced by IL-6 in the case of M1 cells and by 12-O-
tetradecanoylphorbol-13-acetate (TPA) in TF-1 cells, whereas, physiologically, M-CSF 
and IL-3 are the cytokines responsible for monocyte differentiation. In the present study, 
Tal1 mRNA expression was studied in primary CMPs differentiating ex vivo into 
macrophages and also in LPS/IFN-γ activated macrophages. Previously reported findings 
in this system, in terms of morphology, cell surface marker expression and expression of 
known macrophage-specific genes, were verified in cells generated with our hands. 
Finally, using a different strategy developed by Stanley and colleagues, Tal1 protein 
expression was detected in monoblasts and promonocytes isolated from mouse BM and 
also at subsequent differentiation stages. 
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Results 
 
A. Tal1 mRNA expression during differentiation of CMPs to macrophages 
CMPs were isolated by a previously described method (Tagoh et al., 2002) of 
enriching lin- cells from mouse BM and purifying the c-kithigh/CD-31high/Ly6Cneg 
population. These cells were induced to differentiate to macrophages in presence of MM-
specific growth factors. Using quantitative RT-PCR analysis, Tal1 mRNA expression 
was detected at all stages from CMPs to post-mitotic macrophages (Fig. 3A). Although 
Tal1 message fluctuated in abundance, it was detectable throughout, as well as in LPS- 
and IFN-γ-activated macrophages, although at lower levels than unactivated cells (Fig. 
3A). 
 
B. Verification of macrophage formation by the ex vivo culture system used 
Formation of macrophages using the ex vivo culture system used was verified by 
morphological analysis of Wright-Giemsa stained cytospin preparations (Fig. 3B). Cells 
at day 0 and 1 in culture were smaller and spherical, with the nucleus occupying the 
majority of the cell space, while with differentiation, the cells became larger, vacuolated 
and more heterogenous in shape. RT-PCR analysis of genes encoding for macrophage 
specific markers like lysozyme and Csf1r showed the expected increase with 
differentiation, while inducible nitric oxide synthase (iNOS) mRNA expression could be 
detected only in activated macrophages (Fig. 3C). Genes for transcription factors like 
Gata2 and Pu.1 were down-regulated (Tagoh et al., 2002) while p16(Ink4a) mRNA 
expression increased with differentiation (Fig. 3C). Bone-resorptive osteoclast cells are 
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formed from fusion of MM precursor cells and require the presence of receptor activator 
of nuclear factor κβ (RANK)-ligand and M-CSF. Osteoclasts are characterized by 
expression of calcitonin receptor (CALCR) gene expression, which could not be detected 
in these cells, excluding the formation of osteoclasts by the culture system used (data not 
shown). In addition, expression of cell surface antigens, CD31 and Ly6C, were also 
studied during the culture system. As described (Tagoh et al., 2002), expression of those 
two antigens changed sequentially from CD31+Ly6C- CMPs to CD31+Ly6C+, CD31-
Ly6C+, and CD31-Ly6C- cells (Fig. 3D). 
 
C. Tal1 protein expression in MM precursor cells 
Finally, a more mature population of MM precursors comprised of monoblasts 
and promonocytes were enriched using a method developed by Stanley and colleagues 
(Tushinski et al., 1982; Guilbert and Stanley, 1986; Stanley, 1990). These cells were 
induced to differentiate in vitro using recombinant murine M-CSF. Western blot analysis 
with cellular extracts prepared at days 1, 4, 6 and 8 in culture showed modest changes in 
Tal1 expression during this period (Fig. 3E). 
 
Conclusion 
The above studies, for the first time, detected Tal1 expression in primary cells 
differentiating towards macrophages and also in activated macrophages. Quantitative 
gene expression analysis in CMPs to macrophages was complemented with more 
definitive Tal1 protein detection in a mature population of MM precursors. The level of 
Tal1 did not significantly change during the process, consistent with a biological function 
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for this transcription factor in this lineage. The explant model of monocytopoiesis was 
also verified by testing gene expression analysis and expression of cell surface antigens. 
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 Figure 3—cont. 
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Figure 3. Tal1 gene expression during in vitro differentiation of murine MM precursors 
to macrophages. (A) Total RNA prepared from purified precursors and differentiated 
cells at indicated times in culture were reverse transcribed for real-time PCR analysis 
employing SYBR Green fluorescence. Each bar represents mean ± SD from 3 
independent PCR reactions as normalized to RPS16 mRNA expression and is 
representative of three independent experiments. (B) Morphology of differentiating cells 
from Wright-Giemsa stains of cytospin preparations. (C) Gene expression analysis during 
in vitro differentiation of CMPs using quantitative real-time PCR.  The genes tested were 
lysozyme (m-Lys), colony stimulating factor-1 receptor (Csf1r), Gata2, Pu.1, inducible 
nitric oxide synthase (iNOS) and p16(Ink4a), as expressed in arbitrary units relative to 
RPS16 mRNA expression. Each bar represents mean ± S.D. of triplicate PCR 
experiments and is representative of three independent experiments. (D) Flow cytometry 
analysis of cell surface expression of CD31 and Ly6C during in vitro differentiation of 
CMPs. Arrows detail order of progression of differentiation. (E) Western blot analysis of 
Tal1 protein expression in terminally differentiating mouse BM MM precursors. Results 
are representative of two independent analyses. (F) Graph of normalized Tal1 expression 
from Western blot analysis. 
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CHAPTER IV 
 
OVER-EXPRESSION OF TAL1 AND EFFECTS ON MONOCYTOPOIESIS 
 
Introduction 
Gain-of-function studies have been informative in defining transcription factor 
potential in driving particular cell-fate choices. Tal1 was continuously expressed during 
monocytopoiesis with the level of expression changing only modestly during this process. 
This suggested that there could be a specific role of this transcription factor in monocyte 
production, and we aimed to stud that by over-expressing Tal1. Ectopic expression of 
TAL1 in HSCs (Elwood et al., 1998) and hematopoietic progenitor cells (Valtieri et al., 
1998) resulted in increased size and number of erythroid and megakaryocytic colonies 
and also stimulated proliferation in erythropoiesis (Valtieri et al., 1998). Moreover, 
heterodimerizing- and DNA binding-defective TAL1-mutants did not exhibit these effects 
(Valtieri et al., 1998), which suggested that direct protein or DNA interaction was 
required. Interestingly, although enforced expression of TAL1 resulted in inhibition of 
granulocytic and granulo-monocytic CFUs, it did not have any effect on the number of 
monocytic CFUs and markedly increased the number of primary and secondary 
macroscopic colonies containing monocytic cells (Valtieri et al., 1998). 
In this study, Tal1 cDNA was retrovirally delivered to a committed population of 
wild-type BM cells comprised of monoblasts and promonocytes, and gene expression 
was compared with cells transduced with an empty vector or a DNA binding-defective 
mutant of Tal1. 
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Results 
 
A. Semi-quantitative and quantitative gene expression analysis 
The MSCV-based retroviral vector MSCV-IRES-GFP was used to transduce BM 
MM precursor cells with cDNAs encoding wild-type Tal1 or a DNA binding-defective 
Tal1 mutant (Tal1T192P). Empty vector-transduced cells were used as a control. Cells that 
expressed GFP were sorted using a cell sorter and put into culture and induced to 
differentiate in the presence of M-CSF. Gene expression analysis by semi-quantitative 
PCR for Csf1r and Il6-r transcripts showed up-regulation of both genes in Tal1 over-
expressing cells (Fig. 4A). Interestingly, cells transduced with Tal1T192P cDNA did not 
show any difference in Csf1r or Il6-r mRNA abundance compared to vector-transduced 
control and suggested that up-regulation of at least these two genes in Tal1 over-
expressing cells required direct DNA-binding. Expression of CALCR gene expression 
could not be detected in any of the three groups of cells (data not shown). 
The monoblastic leukemia cell line, M1 can be induced to differentiate by IL-6, 
and previous studies revealed that with differentiation, Tal1 expression was abrogated 
along with loss of Tal1-E protein DNA-binding activity (Voronova and Lee, 1994). 
However, Tal1 over-expressing M1 cells, when induced to differentiate, showed an 
earlier and higher expression of Csf1r compared to cells transduced with either Tal1T192P 
cDNA or empty vector (Fig. 4B). Expression of Il6-r gene was also slightly higher in 
Tal1 over-expressing cells compared to control cells or cells expressing Tal1T192P (Fig. 
4C). Moreover, expression levels of both genes were equivalent in empty vector-
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transduced and Tal1T192P transduced cells, suggesting that the DNA-binding ability of 
Tal1 was required for augmentation of Csf1r and Il6-r gene expression. Therefore, these 
findings were similar to those obtained from analysis of BM MM precursor cells. 
 
B. Microarray analysis of genes up-regulated in Tal1 over-expressing cells 
To assess differences in gene expression and function of MM precursor cells after 
Tal1 over-expression, a global gene expression profiling analysis was done using cDNA 
microarrays. Cells transduced with either empty vector or the MSCV-GFP-Tal1 virus 
were sorted and put into differentiation-inducing culture conditions for 8 days and finally 
used for isolation of total RNA. Arrays were hybridized with cDNAs prepared from these 
samples and analyzed for genes that showed greater than two-fold up-regulation in Tal1 
over-expressing cells. Approximately 200 genes were expressed at a higher level 
compared to the control. Analysis of those 200 genes using Ingenuity software identified 
up-regulation of 68 different biological functions. Post-screening, relevant pathways that 
were significantly enhanced included immune response and antigen presentation 
functions and also pathways involving cell signaling, proliferation, cell cycling and gene 
expression (Fig. 5). Individual genes that participate in each pathway are shown in Table 
1. This study suggests that Tal1 over-expression potentiates the differentiation machinery 
by enhancing proliferative potential and cell signaling in MM precursors. Moreover, 
increased antigen presentation and immunological activity suggest that Tal1 may also 
lead to functional enhancement of MM precursors. 
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Conclusion 
In summary, these studies show that TAL1 has a positive role to play in MM 
differentiation. Over-expression of Tal1 in primary MM precursor cells potentiates the 
expression of macrophage-specific genes, which suggests that Tal1 co-operates with the 
differentiation process. Even for M1 cells in which Tal1 expression declines with 
progression of differentiation, Tal1 exerts a positive effect in the mechanism and does not 
block macrophage differentiation. Moreover, these effects of Tal1 were not seen in cells 
transduced with the DNA binding-defective mutant of Tal1 (Tal1T192P) suggesting that 
Tal1 binds DNA sequences to enhance gene expression. Expression of CALCR, which is 
a marker for osteoclast-specific differentiation, was also not detectable in either Tal1-
transduced, Tal1T192P-transduced or empty vector-transduced cells, suggesting that there 
was no shift in lineage commitment in these cells due to Tal1 over-expression. 
Finally, microarray gene expression studies have identified a potential 
enhancement of differentiation- and macrophage function-specific pathways and 
processes with Tal1 over-expression in this lineage. Previous studies have also identified 
similar up-regulation of immune response pathways on enhancement of Tal1 expression 
levels (Landry et al., 2008). However, Tal1 mRNA levels were not elevated in activated 
macrophages (Fig. 3A), which suggests that this could also be secondary effects of 
increased cell signaling and cell surface receptor expression. Nevertheless, Tal1 over-
expression studies do suggest an active role of Tal1 in MM precursors and point towards 
a critical function of this transcription factor in development of this lineage. 
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 Figure 4. Comparative gene expression analysis in MM precursor cells (A), and M1 cells 
(B & C) transduced with wild-type Tal1 cDNA, Tal1T192P cDNA and empty vector. (A) 
Total RNA extracted from day 3 MM precursor cells were reverse transcribed and serial 
dilutions of cDNA were analyzed by semi-quantitative PCR for 25 cycles with primers 
specific for Tal1, Il6-r, Csf1r and RPS16 genes. PCR reaction products were resolved in a 
2% agarose gel and a representative gel from three independent experiments is shown. 
M1 cells were cultured in presence of 50 ng/ml of IL-6 for 4 days and quantitative gene 
expression analysis was done for Csf1r (B) and Il6-r (C) genes at indicated time points. 
Each bar represents mean ± SD from 3 independent PCR reactions as normalized to 
RPS16 mRNA expression. Results are representative of three independent experiments. 
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Figure 5. Results of pathway-analysis of microarray gene expression data. Critical 
pathways up-regulated in Tal1-transduced cells as identified by analysis of 200 genes that 
were found to be greater than two-fold increased compared to control. Dotted line shows 
threshold value for unaffected pathways.  
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Table 1. List of genes connected to pathways that were up-regulated in Tal1 over-
expressing cells. Overlapping gene names denote role in multiple molecular functions. 
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CHAPTER V 
 
TAL1 KNOCKOUT STUDIES IN MM PRECURSOR CELLS 
 
Introduction 
Tal1 expression and over-expression studies indicated an active role of this 
transcription factor during monocytopoiesis, both in terms of regulation of gene 
expression and maturation of MM precursors into macrophages. In addition to its 
expression during differentiation, Tal1 over-expression studies also revealed potentiation 
of macrophage-specific gene expression. On the other hand, a DNA binding-defective 
mutant of Tal1 did not elicit any effect compared to control, and hence, it appears that 
Tal1 binding to target sequences in gene regulatory regions is necessary to regulate 
expression of its target genes. This suggests that a more detailed study of role of Tal1 in 
this lineage is required. A functional analysis of Tal1 can be done most effectively by 
using a strategy of knocking out Tal1 and studying phenotypic effects in this lineage.  
Inactivation of Tal1 has been used effectively to understand its role in other 
hematopoietic lineages like erythrocytes, megakaryocytes and mast cell precursors (Hall 
et al., 2003; Mikkola et al., 2003; McCormack et al., 2006; Salmon et al., 2007). These 
studies have taken advantage of the Cre-Lox system of gene deletion where interferon-
inducible Mx1-Cre transgenic mice were crossed with mice harboring loxP sequences 
flanking Tal1 locus (SCL∆/loxP). However, in the absence of a cell- and stage-specific 
promoter to drive Cre expression in macrophage precursors, an ex vivo approach of gene 
deletion had to be utilized. Mice with loxP sequences flanking Tal1 locus (SCLloxP/loxP) 
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(Hall et al., 2003) and another harboring the LacZ gene knocked into the Tal1 locus in 
one allele (SCLLacZ/WT) (Elefanty et al., 1998) have been previously described. These mice 
were intercrossed to generate SCLloxP/LacZ mice, which were identified by PCR 
amplification of genomic DNA extracted from tail biopsies using primers detailed in 
Materials and Methods (Fig. 6A). Mice with loxP and LacZ sequences gave PCR 
products of 304 bp and 400 bp, respectively, while mice with wild-type alleles gave a 260 
bp product (Fig. 6A).  
MM precursor cells were isolated from the BM of SCLloxP/LacZ mice, using Stanley 
and colleague’s methods (Tushinski et al., 1982; Guilbert and Stanley, 1986; Stanley, 
1990) and retrovirally transduced with MSCV-GFP-Cre vector or empty vector control. 
Cre expression using these vectors was tested by western blot analysis of whole cell 
lysates prepared from transfected NIH3T3 cells using an antibody to Cre (Fig. 6B). Cells 
positive for GFP fluorescence (Fig. 6C, i & ii) were sorted, put back into culture and used 
for subsequent analysis. 
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Figure 6. Genotyping of mouse genomic DNA and Cre expression by retroviral vector. 
(A) Mouse genotyping by PCR amplification of tail genomic DNA using primer pairs as 
described in Materials and Methods section. Mice harboring one floxed Tal1 allele and 
one LacZ allele (as shown in lanes 1, 4, 5, 6, 8 and 9) were used for Tal1 knockout 
studies. (B) Western blot analysis of Cre expression in whole cell lysates prepared from 
NIH3T3 cells transfected with either empty vector or MSCV-GFP-Cre vector. (C) MM 
precursor cells transduced with GFP-expressing vectors, viewed under visible light (i) or 
fluorescent light (ii) at 20× magnification. 
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Results 
 
A. Efficiency of Cre-mediated deletion of Tal1 gene in MM precursor cells 
BM MM precursor cells from SCLloxP/LacZ mice transduced with either MSCV-
GFP-Cre vector or empty vector were sorted on the basis of green fluorescence. Cells 
were put into culture under identical conditions and equal starting cell numbers and 
induced to differentiate in presence of M-CSF (Tushinski et al., 1982; Guilbert and 
Stanley, 1986). The efficiency of Cre-mediated Tal1 deletion was tested by amplification 
of genomic DNA from day 8 culture cells using primers specific for the excised and 
intact loci (Fig. 7A) (as described in Materials and Methods). Semi-quantitative PCR 
analysis showed a preponderance of excised loci in day 8 cells and a much smaller 
number with an intact locus, at this time point in culture (Fig. 7A). Presence of cells with 
intact locus could be a result of less than 100% efficiency in Cre-mediated deletion or 
because of contaminating pseudo-selected cells that may have been incorporated during 
sorting. Another reason could be the competitive growth advantage of Tal1-containing 
(as described later) compared to Tal1-null cells. In any case, RT-PCR analysis showed 
almost complete abolition of Tal1 expression at all time points studied in targeted 
compared to vector-transduced cells (Fig. 7B). Thus, if anything, the presence of cells 
with the Tal1 locus still intact (Fig. 7A) might have underestimated the extent of the Tal1 
knockout (Fig. 7B).  
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Figure 7. Efficiency of Cre-mediated Tal1 gene deletion (A) Semi-quantitative PCR 
analysis of genomic DNA from MM precursors isolated from SCLloxP/LacZ mice and 
transduced with MSCV-GFP-Cre, cultured for 8 days after sorting. Primers described in 
Materials and Methods section were used to differentiate excised and intact Tal1 locus. 
(B) Real-time PCR analysis of Tal1 mRNA abundance in MM precursor cells isolated 
from SCLloxP/LacZ mice and transduced with parental MSCV-GFP vector (SCLloxP/LacZ) or 
MSCV-GFP-Cre vector (SCL∆/LacZ). Total RNA was prepared at the indicated times. Each 
bar represents mean ± SD from 3 independent PCR reactions as normalized to RPS16 
mRNA expression and is representative of six independent experiments. 
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B. Tal1 gene knockout impairs proliferation in MM precursor cells 
Cell counts at timed intervals in culture showed a severe proliferative defect in 
Tal1 knockout (SCL∆/LacZ) compared to vector-transduced cells (SCLloxP/LacZ) (Fig. 8A). 
While cells infected with the control vector increased in number by three-fold during the 
culture period, Cre-transduced cells showed little or no change. Toxic effects of Cre 
expression (Fig. 8B) or retroviral infection (data not shown) were ruled out by 
transduction of wild-type cells with a Cre expression plasmid or empty vector, 
respectively, with both populations found to proliferate at similar rates to non-transduced 
cells. In comparison, Tal1 over-expressing cells showed a higher proliferative capacity 
compared to wild-type cells (Fig. 8C). Finally, in three independent experiments, 
heterozygous knockout cells accumulated in slightly lower numbers than wild-type cells, 
although this was not apparent until later times in culture (days 6 and 8) (Fig. 8C and 
8D). Thus, loss of Tal1 gene expression in differentiating MM precursors significantly 
impaired cellular proliferation, with Tal1 gene expression correlating closely with 
proliferative potential. 
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Figure 8. Effect of increase or loss of Tal1 expression on proliferation of MM precursors 
in vitro. Retrovirally transduced GFP-expressing cells were sorted and cultured under 
identical conditions at equivalent initial cell concentrations. Number of cells per plate 
over a 8 day culture period for SCLloxP/LacZ and SCL∆/LacZ MM precursors (A), wild-type 
MM precursors transduced with MSCV-GFP or MSCV-GFP-Cre (B), and wild-type MM 
precursors transduced with MSCV-GFP-Tal1 or MSCV-GFP-Cre, SCLloxP/WT MM 
precursors transduced with MSCV-GFP-Cre, and SCLloxP/LacZ MM precursors transduced 
with MSCV-GFP-Cre in exponential scale (C) and linear scale (D). Each data point 
represents mean ± SD from triplicate determinations, with similar trends noted in three 
independent experiments. 
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To quantify this proliferative defect in SCL∆/LacZ cells in a more accurate fashion, 
a flow-cytometric approach was used to measure rate of cell division in SCL∆/LacZ cells. 
Before sorting the cells on the basis of GFP expression, cells were stained with a 
membrane-intercalating, red fluorescent dye, PKH26, and only those cells that were 
positive for both GFP and PKH26 fluorescence were sorted and put into culture. Initial 
PKH26 staining was also analyzed at that time point and >98% of cells were modeled 
into a single parent generation (first generation, Fig. 9A i and iv). In culture, a faster rate 
of cell division would result in a faster decrease in PKH26 fluorescence as measured at 
subsequent time points by flow cytometry. Both SCLloxP/LacZ and SCL∆/LacZ cells were 
cultured under identical conditions and at equal starting cell numbers and were examined 
at days 6 and 8 for loss of PKH26 fluorescence from cell division. Loss of PKH26 
fluorescence was analyzed and a model describing 3 or more generations of cells over the 
6-8 day culture period best fit the data. Theoretically, three generations of cells should 
correspond to a four-fold [2(3-1)] increase in cell number relative to the first generation. 
Thus, the increase in numbers of control SCLloxP/LacZ cells (Fig. 8A) was only slightly less 
than that predicted from dye dilution studies. After 6 days, 34.8% of SCL∆/LacZ cells were 
still first generation, 46.8% were second generation, and only 17.8% were classified as 
third generation (Fig. 9A, v). Over the same time period, 13.8% of control SCLloxP/LacZ 
cells were first generation, 21.1% second generation, and 62.8% third generation (Fig. 
9A, ii). While slightly less than half of SCL∆/LacZ cells (48.9%) were second generation 
after 8 days in culture, most SCLloxP/LacZ cells were in third generation, with some fourth 
generation cells (6.5%) also represented (Fig. 9A, iii and vi). 
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PKH26 fluorescence during cell culture was also measured as mean fluorescence 
of the population and showed a faster decrease in control SCLloxP/LacZ cells compared to 
SCL∆/LacZ cells (Fig. 9B). The control cells showed a mean fluorescence of 307.01 at day 
1, which decreased to 55.53 at day 4, 49.98 at day 6 and finally to 34.28 on day 8. On the 
other hand, SCL∆/LacZ cells had an initial fluorescence of 191.59 (day 1) which declined to 
68.19 (day 4), 67.68 (day 6) and finally to 53.89 (day 8) (Fig. 9B). Therefore, while 
PKH26 fluorescence for control cells decreased by 88.83% over the culture period that 
for SCL∆/LacZ cells showed 71.9% decrease under similar conditions. 
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Figure 9. Proliferation analysis by PKH26 staining (A) GFP+PKH26+ cells were isolated 
using dual-color FACS and placed in culture under identical conditions at equivalent 
initial concentrations. Day 1 cells were modeled to represent generation I, and loss of 
PKH26 fluorescence intensity due to cell division, measured at days 6 and 8, were 
modeled as shown. The data depicted are representative of three independent 
experiments. Gen, generations. (B) Comparison of PKH26 dye dilution in SCLloxP/LacZ 
(black) and SCL∆/LacZ (red) cells plotted according to PKH26 incorporation. Mean 
fluorescence is shown. 
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C. Tal1 gene knockout results in modest increase in apoptosis 
An early hallmark of apoptotic cells is breakup of phospholipid asymmetry of 
plasma membrane and exposure of phosphatidylserine (PS) residues which are 
translocated to the outer layer of the membrane. Annexin V preferentially binds exposed 
PS groups in the cell membrane and is widely used to detect early apoptotic events. APC-
Annexin V staining of cells enables identification and quantification of apoptotic cells on 
a single-cell basis using flow cytometry. Bivariate analysis of cells stained with APC-
Annexin V and 7-AAD (which binds DNA) can discriminate intact cells (APCneg7-
AADneg) from early apoptotic (APCpos7-AADneg) and late apoptotic or necrotic cells 
(APCpos7-AADpos). To determine whether the reduced accumulation of SCL∆/LacZ cells 
was attributable to decreased viability, apoptosis was analyzed using Annexin V and 7-
AAD staining, with non-apoptotic cells characterized by their ability to exclude both 
stains (Fig. 10). The percentage of viable cells in the SCL∆/LacZ group was very slightly 
decreased compared to SCLloxP/LacZ cells at days 4 and 6 but was not different at days 1 
and 8 of culture. These results showed that Tal1 gene loss had minimal effects on cell 
survival and that apoptosis did not account for the marked reduction in cell number 
observed. 
 
53 
 
  
Figure 10. Apoptosis analysis of SCLloxP/LacZ and SCL∆/LacZ MM precursor cells. Viability 
was determined by flow cytometry analysis of cells and defined as negative for APC-
Annexin V binding and 7-AAD staining. Three plates of cells per group were analyzed at 
each of the indicated time points and each bar represents mean percentage ± SD of cells 
negative for both markers. 
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D. Tal1 gene knockout results in slight acceleration in differentiation 
Differentiation of MM precursor cells can be tracked by expression of cell surface 
markers CD31 and Ly6C (Fig. 3D) (Tagoh et al., 2002). Flow cytometry analysis was 
used to assess expression of these two markers and to determine presence of most mature 
cells (of phenotype CD31-Ly6C-) in SCLloxP/LacZ and SCL∆/LacZ groups at three different 
time points in culture (Fig. 11A). Higher percentages of the most mature CD31-Ly6C- 
cells were noted in SCL∆/LacZ (59.2% at day 2 and 91.2% at day 4) compared to 
SCLloxP/LacZ populations (52.2% at day 2 and 82.6% at day 4) at early times in culture. 
Moreover, the less differentiated CD31-Ly6C+ cells comprised a lower percentage of 
SCL∆/LacZ cultures (26.9% at day 2 and 8.5% at day 4) than of SCLloxP/LacZ cultures (36.1% 
at day 2 and 16.4% at day 4). 
Another macrophage-specific cell surface marker, F4/80, is expressed in more 
mature cells but not in earlier precursor cells (Hume and Gordon, 1983). However, flow 
cytometry analysis of F4/80 expression did not reliably discriminate between different 
stages of monocytopoiesis in our hands (Fig. 11B). Approximately 90% of cells in both 
groups became F4/80-positive after 24 hr post-sorting and increased by almost equal 
amounts over the next 24 hr. In sum, these data indicate that SCL∆/LacZ cells lacking a 
functional Tal1 gene differentiated somewhat more rapidly than SCLloxP/LacZ cells. 
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 Figure 11. Analysis of differentiation of SCLloxP/LacZ and SCL∆/LacZ MM precursor cells 
(A) Flow cytometry analysis of APC-CD31 (Y-axis) and PE-Ly6C (X-axis) staining of 
SCLloxP/LacZ and SCL∆/LacZ cells at days 1, 2, and 4 of culture. Representative profile from 
three independent experiments is shown. (B) Flow cytometry analysis of F4/80 
expression (X-axis) in SCLloxP/LacZ and SCL∆/LacZ cells at days 1 and 2 of culture. 
Percentage of cells staining positive for APC-F4/80 mAb are denoted. 
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E. Tal1 knockout cells are defective in cell cycle progression 
SCL∆/LacZ cells showed a significant decrease in cell proliferation which could not 
be explained by the modest differences in cell death and differentiation. To better 
characterize the proliferative defect in Tal1 knockout cells, BrdU pulse chase analysis 
was carried out. The immunofluorescent staining of incorporated BrdU (an analog of the 
DNA precursor thymidine) and flow cytometric analysis provide a high resolution 
technique to determine the frequency and nature of individual cells that have synthesized 
DNA. To that end, GFP-expressing cells were isolated, cultured for 3 days, pulse labeled 
with BrdU for 45 min, and then followed through at least one cell cycle by flow 
cytometry. In this method, BrdU is incorporated into newly synthesized DNA by cells 
entering and progressing through S phase of the cell cycle during that 45 min. The cells 
that have incorporated BrdU can then be followed by flow cytometry through different 
phases of the cell cycle by staining with APC conjugated anti-BrdU antibody and 7-AAD 
binding of total DNA. 
Analyzed immediately after pulsing, as expected, the majority of BrdU-labeled 
cells from both the SCLloxP/LacZ and SCL∆/LacZ groups were in S phase (94.9% and 87.3%, 
respectively, Fig. 12A, i and v). At later times, SCLloxP/LacZ cells in S phase progressed 
rapidly to G2/M and then to G0/G1, with a corresponding decrease in the percent in S-
phase (Fig. 12A ii, iii and iv). However, while some SCL∆/LacZ cells advanced to late S 
phase one hr after pulsing, as evidenced by the two peaks of labeling (Fig. 12A, vi), this 
population showed a higher proportion in G0/G1 after 2 and 4 hr (18.1% and 35.2%, 
respectively), lacked a distinct G2/M population (0% and 18.8%, respectively), and 
contained a higher percentage of cells still in S phase (81.9% and 46.0%) compared to 
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control cells (Fig. 12A, vii and viii). These results provide evidence of a slowing in cell 
cycle progression, with delayed traversal of S phase. 
As pulse-chase approach permitted analysis of only those cells able to incorporate 
BrdU during the 45 min pulse, MM precursors were also cultured with BrdU for longer 
times (12, 24, 36, and 48 hr) before analysis by flow cytometry (Fig. 12B). Prolonged 
exposure of cells to BrdU allows for the comprehensive identification and analysis of 
actively cycling, as opposed to non-cycling, cell populations. The SCL∆/LacZ population 
contained a higher proportion (27.5% vs. 7.6% for SCLloxP/LacZ cells, Fig. 12B, iv and viii) 
of cells that never incorporated BrdU over the 48 hr labeling period. 
Finally, to differentiate G0 and G1 population in both groups, flow cytometric 
analysis of cellular DNA and RNA content were done by staining with Hoechst 33342 
and Pyronin Y dyes respectively.  Cells in G0 have lower amounts of RNA and therefore 
lower Pyronin Y staining, while cells in G1 phase show greater staining due to their 
higher RNA content. Analysis of DNA/RNA staining showed a three-fold higher 
percentage of a quiescent or G0 population in SCL∆/LacZ cells (12.7%) compared to 
control SCLloxP/LacZ cells (4.6%) (Fig. 13). Taken together, these studies suggest a role for 
TAL1 in cell cycle progression in MM precursors that largely explains the proliferative 
defect associated with homozygous Tal1 gene loss. 
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Figure 12. Cell cycle analysis of SCLloxP/LacZ and SCL∆/LacZ MM precursor cells. (A) Flow 
cytometry analysis of BrdU incorporation vs. DNA content by 7-AAD staining for 
SCLloxP/LacZ and SCL∆/LacZ cells at 0, 1, 2, and 4 hr after pulsing. G0/G1, S, and G2/M 
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populations were modeled computationally. A representative profile from multiple 
independent experiments is shown. (B) Flow cytometry analysis of SCLloxP/LacZ and 
SCL∆/LacZ cells cultured with BrdU for 12, 24, 36, and 48 hr. DNA content (X-axis) is 
plotted vs. BrdU incorporation (Y-axis). Numbers inside the upper and lower quadrants 
denote the percentage of BrdU-positive and -negative cells, respectively. 
 
 
 
 
Figure 13. DNA/RNA content analysis of SCLloxP/LacZ and SCL∆/LacZ cells. Cells were 
cultured for three days after sorting of GFP-positive cells. DNA was stained with Hoechst 
33342 and RNA was stained with Pyronin Y and analyzed by flow cytometry to identify 
Hoechst33342lowPyronin Ylow (G0) population or Hoechst33342lowPyronin Yhigh (G1) 
population. 
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F. Gene expression analysis in Tal1 over-expressing and Tal knockout cells 
Tal1, a bHLH transcription factor, could regulate downstream target genes in MM 
precursor cells. Identification of those target genes could explain the phenotype and also 
illuminate the functions of Tal1 in this lineage. To that end, gene expression analysis was 
carried out with wild-type, Tal1 over-expressing and in Tal1 knockout cells at different 
times in culture. Since alteration in Tal1 expression affected cell cycle progression and 
proliferation of these cells, the expression of several candidate genes encoding 
transcription factors and cell cycle regulators was tested. 
By real-time PCR analysis, mRNA expression was quantified in Tal1+/+, Tal1 
over-expressing and Tal1 knockout (SCL∆/LacZ) cells at days 1, 4, 6 and 8 in culture (Fig. 
14). The same bicistronic retroviral vector used to deliver Cre to MM precursors to 
inactivate the floxed Tal1 allele mice was also employed in over-expressing Tal1 in wild-
type cells. As expected, expression of Tal1 gene was highly up-regulated in Tal1 over-
expressing cells and considerably abrogated in SCL∆/LacZ cells compared to wild-type 
controls (Fig. 14A). Of particular significance, Gata2 mRNA was reduced seven- and 
four-fold, respectively, at days 1 and 4 in Tal1-/- (SCL∆/LacZ) relative to Tal1+/+ cells (Fig. 
14B). Although the level of Gata2 expression decreases physiologically during 
differentiation of MM precursors [Fig. 3C and (Tagoh et al., 2002)], Tal1-/- (SCL∆/LacZ) 
cells showed even lower Gata2 expression than Tal1+/+ controls at days 6 and 8. In 
contrast, enforced Tal1 expression did not increase the abundance of Gata2 mRNA at any 
time examined (Fig. 14B). Genes encoding other transcription factors, previously 
identified to be critical for monocytopoiesis, including PU.1, Runx1, Lmo2, Lmo4, 
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C/EBPα and C/EBPβ, were not significantly affected by the change in expression of 
Tal1. 
Because of the delay and reduction in cell cycle progression observed with Tal1 
gene loss (Fig. 12 and 13) and the published evidence for their regulation by E proteins, 
the genes for several cyclin-dependent kinase (CDK) inhibitors were investigated. 
p16(Ink4a), which is a target of repression by Tal1 (Park and Sun, 1998; Hansson et al., 
2003; O'Neil et al., 2004), was up-regulated approximately 3-4 fold in SCL∆/LacZ cells and 
reduced, albeit to a lesser extent, in Tal1 over-expressing cells (Fig. 14C). In contrast, 
expression of p21(Cip1), another putative target of Tal1 and E protein regulation (Prabhu 
et al., 1997; Park and Sun, 1998; Liu et al., 2004), was only slightly increased in 
SCL∆/LacZ compared to SCLloxP/LacZ cells (days 6 and 8, Fig. 15A). While elevation in 
p16(Ink4a) and p21(Cip1) could have contributed to the cell cycle delay observed in Tal1 
knockout cells, especially given the phase of the cell cycle affected, the only slight 
reduction in p16(Ink4a) mRNA cannot explain the increased proliferation of Tal1 over-
expressing cells (Fig. 8C). 
Expression of the gene encoding the transmembrane receptor, Csf1r was also 
found to be slightly up-regulated in SCL∆/LacZ cells at later time periods (days 4, 6 and 8 
in culture) compared to control (Fig. 15B). This could relate to the slightly enhanced rate 
of differentiation noted in Tal1 knockout cells (Fig. 11A). Finally, Tal1 over-expression 
up-regulated both Csf1r and Il6-r mRNA expression (Fig. 4A) and also pathways related 
to cell signaling and overall growth and proliferation (Fig. 5), which could have together 
contributed to the high proliferative potential in these cells. 
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Figure 14. Tal1 (A), Gata2 (B), and p16(Ink4a) (C) gene expression analysis. Wild-type 
MM precursor cells were transduced with Cre or Tal1 cDNA and in SCLloxP/LacZ MM 
precursor cells transduced with Cre cDNA (SCL∆/LacZ). Cells were grown in culture for 
the indicated times after sorting and transcript abundance measured by real-time RT-PCR 
analysis. PCR reactions were done in triplicate and expressed in arbitrary units relative to 
RPS16 mRNA expression. Expression profile shown is representative of three 
independent experiments. 
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Figure 15. Expression of p21(Cip1) (A) and Csf1r (B) mRNA during differentiation of 
SCLloxP/LacZ and SCL∆/LacZ MM precursor cells. Cells were grown in culture for the 
indicated times after sorting and transcript abundance measured by real-time RT-PCR 
analysis. PCR reactions were done in triplicate and expressed in arbitrary units relative to 
RPS16 mRNA expression. Expression profile shown is representative of two independent 
experiments. 
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G. Tal1 functions in MM precursor cells require direct DNA binding 
TAL1 regulates transcription both through direct binding to DNA and as a non-
DNA-binding cofactor (Wadman et al., 1997; Ono et al., 1998; Xu et al., 2003). To 
determine whether the proliferative defect in SCL∆/LacZ cells would be rescued by a wild-
type Tal1 cDNA, SCLloxP/LacZ MM precursors were transduced with the MSCV-GFP-Cre 
vector together with MSCV-YFP-Tal1, while cells transduced with the two parental 
vectors were used as a control. Equal numbers of GFP- and YFP-expressing cells were 
then sorted and cell numbers determined at timed intervals in culture. These studies 
showed that the defective proliferation of Tal1 knockout cells was completely rescued by 
the Tal1 cDNA, with the growth curve of Tal1-transduced SCL∆/LacZ cells virtually 
identical to that of control cells (Fig. 16). Since Tal1 deletion resulted in down-regulation 
of Gata2 expression, a Gata2 cDNA was also tested in this rescue assay. However, cells 
transduced with the Gata2 cDNA were nonviable after only 1 day in culture, likely 
reflecting an adverse effect of Gata2 over-expression in a Tal1-null background (data not 
shown). Finally, to investigate whether DNA-binding activity was required for TAL1 
function in MM proliferation, SCL∆/LacZ cells were transduced with the cDNA of a well-
characterized DNA binding-defective mutant of Tal1, T192P (Huang and Brandt, 2000). 
Importantly, cells transduced with this cDNA behaved identically to SCL∆/LacZ cells and 
exhibited no recovery in proliferative capacity (Fig. 16). This result indicates that, similar 
to its actions in erythroid differentiation (Kassouf et al., 2008), Tal1 DNA-binding 
activity was absolutely required for outgrowth of murine MM precursors in explant 
cultures. 
65 
 
  
Figure 16. Rescue analysis in Tal1 knockout cells. Cell counts in MM precursors from 
SCLloxP/LacZ mice simultaneously transduced with MSCV-GFP-Cre and either a Tal1 or 
Tal1T192P cDNA in the retroviral vector MSCV-IRES-YFP. Dual-color FACS was used to 
sort GFP- and YFP-expressing cells. The Tal1T192P cDNA encodes a DNA binding-
defective protein. Parental vector-transduced cells were used as controls, and total 
number of cells per plate for each day is plotted. Each data point represents mean ± SD 
from 3 plates of cells. 
 
Conclusion 
Tal1 gene knockout studies identified a novel function of this transcription factor 
in the monocyte-macrophage cell lineage. An ex vivo approach of gene deletion in MM 
precursor cells enabled the study of specific phenotypes of Tal1 knockout and also 
facilitated understanding of the molecular basis of the actions. Tal1 regulated the 
proliferative potential of MM precursor cells in a Tal1 dose-dependent manner, with Tal1 
over-expressing cells being highly proliferative, and even 50% reduction in Tal1 
expression produced a significant difference in cell accumulation (Fig. 8C). This 
proliferative defect was brought about by the cell cycle regulatory effects of Tal1, as the 
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BrdU pulse chase analysis showed that Tal1 knockout cells were slow in traversal 
through S phase. The prolonged exposure to BrdU detected higher percentage of non-
cycling cells in Tal1 knockout population at all time points and also showed relatively 
more cells in G0 compared to G1 phase by Pyronin Y and Hoechst 33342 staining. This 
suggested that a combination of slowdown in S phase traversal and a relatively higher 
population of non-cycling cells in SCL∆/LacZ group resulted in the proliferative defect of 
these cells. 
Molecular gene expression analysis at different time points in culture identified 
two potential targets of Tal1 transcription factor, p16(Ink4a) and Gata2. While 
p16(Ink4a) gene expression was found to be up-regulated in SCL∆/LacZ cells, Gata2 
mRNA expression was reduced, suggesting a dual role for Tal1 in both up-regulating and 
down-regulating target gene expression. Expression of another CDK-inhibitor p21(Cip1), 
was also found to be up-regulated, although not to the same extent as p16(Ink4a), in 
SCL∆/LacZ cells. Interestingly, with Tal1 over-expression, Gata2 expression did not change 
compared to control, and p16(Ink4a) expression decreased by a very small amount which 
cannot sufficiently explain the high proliferative potential of Tal1 over-expressing cells. 
Conceivably, up-regulation of genes encoding Csf1r and Il6-r, in Tal1 over-expressing 
cells resulted in increased sensitivity to growth factors and contributed to their high 
proliferative potential (Fig. 4). 
Up-regulation of CDK-inhibitors is connected with cell cycle delay (Sherr and 
Roberts, 1999) and in this case, may have contributed to the phenotype observed in Tal1-
null cells. Moreover, Gata2 regulates cell cycle progression in G1ME cells (Huang et al., 
2009) and could have contributed to the delay in cell cycle progression. Decreased Gata2 
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expression in G1ME cells also correlated with up-regulation of myeloid gene expression 
(Huang et al., 2009), similar to what was seen in MM precursors in which reduced Gata2 
expression in SCL∆/LacZ cells led to increased Csf1r expression (Fig. 14B and 15B). 
Reduction in Gata2 expression accelerates differentiation in adipocytes (Tsai et 
al., 2005; Okitsu et al., 2007) and monocytes in juvenile myelo-monocytic leukemia 
(JMML) patients (Yang et al., 2009). This could explain the enhanced differentiation 
seen in SCL∆/LacZ MM precursor cells at early culture periods (Fig. 11A). Interestingly, 
rescue attempt by re-introduction of Gata2 cDNA in SCL∆/LacZ cells resulted in complete 
loss of cell viability (data not shown). Earlier studies have documented a complete loss of 
colony-forming ability of BM progenitor cells over-expressing Gata2 although those 
cells remained completely viable. Therefore, the high rate of cell death observed in 
rescue of SCL∆/LacZ cells with Gata2 could be due to an adverse effect of Gata2 over-
expression in a Tal1-null background. 
Finally, re-introduction of a Tal1 cDNA resulted in complete rescue of the 
proliferative defect of MM precursor cells, which suggests that the SCL∆/LacZ phenotype 
was due to loss of the Tal1 gene directly and not due to any indirect effect. Moreover, the 
DNA-binding mutant of Tal1 did not exhibit recovery of proliferative capacity, indicating 
that, similar to its actions in erythroid differentiation (Kassouf et al., 2008), Tal1 DNA-
binding activity was absolutely required for outgrowth of murine MM precursors in 
explant cultures. 
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CHAPTER VI 
 
TAL1 DNA BINDING IN MM PRECURSOR CELLS AT GENE REGULATORY 
REGIONS  
 
Introduction 
Tal1 is a class II bHLH transcription factor that can heterodimerize with class I 
bHLH proteins called E proteins and recognize specific E box sequences (CANNTG) in 
gene regulatory regions. The E box-binding element preferred by this heterodimer is 
CAGATG, with preference extending to two bases on either side of the E box as well 
(Hsu et al., 1994a). A multimeric complex consisting of TAL1-E protein heterodimer 
bound to an E box, and bridged by Ldb1 and LMO2 to a GATA protein bound to a 
GATA site 9-12 bp away was also identified in MEL cells (Wadman et al., 1997; Xu et 
al., 2003; Xu et al., 2007). As a result of its association at gene regulatory regions with 
different partners, Tal1 activates and represses transcription of target genes, this being 
critical not only in specification of hematopoietic cell fate and vasculogenesis but also in 
leukemogenesis. 
Tal1-E protein complexes bind DNA with a reduced transactivation potential 
compared to E protein homodimers (Hsu et al., 1994c; Park and Sun, 1998) and can also 
repress the transcription of genes with E box sequences in their promoter. This has been 
shown previously in reporter experiments with promoter regions of several genes 
including p16(Ink4a), p21(Cip1) and pTα (Prabhu et al., 1997; Funato et al., 2001; 
Hansson et al., 2003; Liu et al., 2004). Mutational analysis of the upstream E box 
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sequences in promoter regions have shown that those elements are critical for full 
transcriptional activation by E proteins and co-expression of Tal1 resulted in repression 
of this activation. This suggested that Tal1 might have a direct role in regulating the 
expression of these genes by binding E box sequences in upstream regulatory regions. 
The oncogenic potential of Tal1 may also be related to this characteristic as observed in a 
study done with E2A- or HEB-heterozygous mice (O'Neil et al., 2004). Ectopic 
expression of Tal1 in thymocytes of those mice resulted in T cell differentiation arrest 
and accelerated leukemogenesis suggesting that Tal1 interfering with E protein function 
may be a critical mechanism in developing T cell malignancy (O'Neil et al., 2004). 
Gata2 is expressed in a wide variety of tissues including hematopoietic, 
endothelial and neuronal cells and, Gata2 gain-of-function experiments and in vitro 
differentiation assays in Gata2-/- ES cells showed that it plays a pivotal role in the 
proliferation of early hematopoietic progenitors (Briegel et al., 1993; Tsai and Orkin, 
1997; Kitajima et al., 2002). An E box-GATA motif in an intronic enhancer region (+9.5 
kb) of the Gata2 gene is critical for its expression in endothelial and fetal liver cells 
during embryonic development (Khandekar et al., 2007; Wozniak et al., 2007). This 
single motif was indispensable and sufficient for Gata2 expression in hematopoietic cells, 
whereas for expression in human endothelial cells it required additional regulatory 
modules (Wozniak et al., 2007). Electrophoretic mobility shift analysis (EMSA) showed 
that Tal1-E protein heterodimers could bind with high affinity to this crucial enhancer 
region in vitro, which could be competed with a cold wild-type probe but not one with a 
mutated E box (Khandekar et al., 2007). In reporter assays done in the G1ME and MEL 
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erythroid cell lines, this element showed robust activity, while mutation or removal of the 
GATA sites resulted in abrogation of erythroid enhancer activity (Grass et al., 2006).  
The increase in p16(Ink4a) and reduction in Gata2 mRNA expression in SCL∆/LacZ 
MM precursor cells suggests that Tal1 plays a role in regulating the expression of these 
two genes. Moreover, given the phenotypic abnormalities seen in SCL∆/LacZ cells, de-
regulation of p16(Ink4a) and Gata2 expression seemed to contribute to this defect. Since 
the DNA binding-defective mutant of Tal1 was not able to rescue the defects, it is 
probable that Tal1 function in this lineage is mediated by direct interaction with DNA. 
On that basis, we hypothesized that Tal1 regulates the expression of p16(Ink4a) and 
Gata2 by directly occupying upstream regulatory regions in association with its E protein 
binding partner. 
 
Results 
To identify probable Tal1-binding sites in p16(Ink4a) upstream region we 
scanned a 12 kb region upstream of the translational start site and identified 5 preferred E 
box sequences (CATCTG or CAGATG) for TAL1-E protein binding (bases -13, -2592, -
4638, -5106, and -6932) (Fig. 17A). The preferred E box at -4638 has two other adjacent 
non-canonical E boxes at -4650 and -4719, which could also participate in complex 
formation at this region. MM precursor cells at days 4 and 7 in culture were used for 
ChIP analysis with antibodies to Tal1 and E47 and control IgG. The amount of DNA 
immunoprecipitated was then quantified by real-time PCR analysis using specific primers 
flanking each of these regions or the gene’s 3´ UTR and expressed as a percentage of 
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input. Three of these E boxes, at -2592, -4638 and -5106, were shown by this approach to 
be occupied by Tal1 and E47 in day 4 cells (Fig. 17C). In contrast, no binding was 
detected at -13, -6932, or the 3´ UTR at any time (data not shown), and another, non-
canonical E box in the promoter region (-437) likewise did not show binding (data not 
shown). Finally, Tal1 and, unexpectedly, E47 occupancy of the -2592 and -4638 elements 
were very low and essentially absent at the -5106 E box at day 7 (Fig. 17D), despite the 
increase in p16(Ink4a) expression at this time (Fig. 3C and 14C). This suggests the 
possibility that E proteins other than E47 are involved and/or other mechanisms for 
p16(Ink4a) gene transactivation operate at these later times. 
Another putative Tal1-E protein target is the Gata2 intron 4 (+9.5 kb) enhancer 
region, which consists of three GATA sites and an E box element (Fig. 17B) that 
regulated Gata2 expression in endothelial and hematopoietic cells (Khandekar et al., 
2007; Wozniak et al., 2007). To determine whether Tal1 occupied this region in MM 
precursors, ChIP analysis was carried out as above with antibodies to Tal1 and E47 and 
with IgG as a control. Tal1- and E47-specific antibodies, but not IgG, were able to 
precipitate this intronic fragment from day 4 (Fig. 17C) but not day 7 cells (Fig. 17D), 
concordant with the decline in Gata2 expression over this same time period (Fig. 3C and 
14B). Primer sequences designed for the Gata2 3´ UTR did not support any amplification 
(data not shown), indicating specific occupancy of this intronic region in MM precursor 
cells. 
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Figure 17. Chromatin immunoprecipitation analysis in MM precursor cells. Day 4 and 
day 7 cells were used to detect Tal1 and E47 association at p16(Ink4a) 5' E boxes (A) and 
Gata2 intron 4  E box-GATA element (B). Noncoding exons are denoted by empty boxes 
and coding exons are denoted by solid boxes. The preferred E box sequences in 
p16(Ink4a) upstream region are pointed with dashed lines and non-canonical E boxes 
pointed with solid lines and the 55 bp region in Gata2 intron 4 containing the E box-
GATA element is also shown. Sonicated chromatin fragments from day 4 (C) and day 7 
(D) MM precursor cells, immunoprecipitated with antibodies to Tal1 or E47 or normal 
rabbit IgG were quantified by real-time PCR analysis using region-specific primers. Bar 
represents mean abundance ± SD of each fragment relative to input as determined from 
triplicate PCR amplifications and is representative of three independent experiments. 
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In murine myeloid leukemia cell line M1, p16(Ink4a) protein expression goes up 
with IL-6-induced differentiation (Amanullah et al., 2000) in parallel with a decrease in 
Tal1 expression and Tal1/E protein DNA-binding activity (Voronova and Lee, 1994). As 
this phenocopies the situation with Tal1 gene knockout, ChIP analysis was also carried 
out on chromatin from untreated and IL-6-treated M1 cells for the same regions that were 
tested in primary MM precursor cells. The IgG control did not show binding for any of 
the regions, and the 3' UTR region did not show binding for any of the specific antibodies 
(Fig. 18A). As predicted from the drastic decline in its expression (Voronova and Lee, 
1994), Tal1 occupancy was detected only in uninduced cells and not in cells treated with 
IL-6 for 48 hr (Fig. 18A and 18B). In contrast, E2A association with these same E box 
elements could be detected in both IL-6-treated and untreated cells, indicating that its E12 
and/or E47 protein products would be unopposed by TAL1 to augment expression of this 
gene when these cells differentiate (Fig. 18C).  
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Figure 18. Chromatin immunoprecipitation analysis in M1 cells. ChIP analysis of Tal1 
and E47 binding at p16(Ink4a) 5' E boxes (A)(i) and  Gata2 intron 4 (A)(ii) in M1 cells 
crosslinked with formaldehyde. Sonicated chromatin fragments were immunoprecipitated 
with antibodies to Tal1 (α-Tal1), E47 (α-E47), and control rabbit IgG. Quantitative PCR 
analysis was done with specific primers to compare Tal1 (B) and E2A (C) association, 
relative to input in untreated M1 cell. Some cells were treated with IL-6 for 48 hr. The 
results shown are representative of three independent experiments. 
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Conclusion 
The Tal1-E protein binding studies identified a novel function of these two 
proteins in differentiation of MM precursor cells and demonstrated that the p16(Ink4a) 
and Gata2 genes are direct targets of Tal1in this lineage. It had been previously reported 
that p16(Ink4a) expression could be controlled by Tal1 and E protein association at 
specific E boxes in its promoter region (Nielsen et al., 1996; Park and Sun, 1998; 
Hansson et al., 2003). However, these studies utilized promoter-reporter constructs 
transiently transfected into cell lines; still, they showed that mutation or deletion of these 
E boxes severely affected reporter gene expression. These studies also demonstrated that 
Tal1 is very important for regulation of gene expression, since E protein homodimers 
function as more potent activators of transcription than Tal1-E protein heterodimer. Our 
ChIP analyses carried out in primary MM precursor cells, establish that Tal1-E protein 
heterodimers occupy these gene regulatory regions in the appropriate cell types at the 
appropriate times and suggest a mechanism for Tal1 function in regulating cell 
proliferation and cycling. It also shows that the heterodimer associates selectively with 
certain E box sequences (-2592, -4638 and -5106) but not with the more proximal (-13 
and -437) and the most distal (-6932) E boxes that were analyzed. Finally, the fact that 
Tal1-E47 association is lower at day 7 of culture compared to day 4, although p16(Ink4a) 
gene expression is higher at later times, suggests that other E proteins may also be 
involved with regulation of this gene or that alternative modes of regulation exist. 
The Gata2 zinc finger transcription factor has a critical function in the 
hematopoietic system, and the Gata2 intron 4 enhancer region was regulated by a Tal1-E 
protein complex in endothelial cells and hematopoietic cells (Khandekar et al., 2007; 
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Wozniak et al., 2007). Our findings that the same region is bound in MM precursor cells 
by the Tal1-E protein complex suggest an important function of Tal1 in this lineage. The 
absence of complex association with this intron in day 7 cells correlated with Gata2 
expression in this lineage which decreases with differentiation. This could be an 
important event in macrophage differentiation, since ectopic expression of Gata2 in an 
attempt to rescue the phenotypic defect in SCL∆/LacZ cells resulted in complete loss of cell 
viability. 
Lastly, ChIP analysis of Tal1-E protein association in the M1 leukemic cell line 
show findings similar to primary cells and suggests a mechanism for repression of 
p16(Ink4a) expression in uninduced cells. Differentiation-inducing signals induce 
p(16Ink4a) expression and loss of leukemogenicity (Amanullah et al., 2000) along with a 
decrease in Tal1 expression and abrogation of Tal1-E protein heterodimer (Voronova and 
Lee, 1994).  
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CHAPTER VII 
 
DISCUSSIONS AND FUTURE DIRECTIONS 
 
The studies described above investigate and analyze a previously unknown role of 
bHLH transcription factor TAL1 during monocytopoiesis. Extensive studies have been 
done to identify function of TAL1 in other hematopoietic lineages including erythrocytes, 
megakaryocytes, and mast cells. Although derived from the same progenitor cells as 
these, the CMPs, there is conflicting evidence of TAL1 function in MM precursor cells. 
 Work carried out in a human cell line TF-1, which has the dual potential of 
differentiating towards both erythrocytic and monocytic lineages, found that Tal1 
expression decreased slightly with differentiation (Hoang et al., 1996). The same study 
also showed that constitutive expression of Tal1 resulted in a decrease in adherent cells, 
reflected in reduced immunoreactivity towards CD45 and FcγRII (CD32), which are, 
however, not macrophage-specific markers and do not reliably specify monocytopoiesis. 
Moreover, in the M1 murine myelo-monocytic leukemia cell line that can be induced to 
differentiate to macrophage by both leukemia inhibitory factor (LIF) and IL-6, ectopic 
expression of Tal1 enhanced IL-6-induced differentiation as measured by Mac1α 
expression but perturbed LIF-induced differentiation (Tanigawa et al., 1995). Nuclear 
extracts prepared from uninduced M1 cells were analyzed by EMSA using an E box 
oligonucleotide probe and showed presence of Tal1-E protein heterodimer bound 
specifically to the E box DNA motifs (Voronova and Lee, 1994). However, DNA binding 
of the Tal1-E protein heterodimer became undetectable after 24 hr of IL-6 treatment, 
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when differentiation-induced morphological and molecular changes are initiated in M1 
cells (Voronova and Lee, 1994). In fact, with M1 cell differentiation, Tal1 expression is 
extinguished and expression of dominant-negative HLH proteins Id1, and primarily Id2, 
is increased, while E12 and E47 protein expression is unaffected (Voronova and Lee, 
1994).  
However, several groups have detected Tal1 expression in primary mouse 
macrophages and peripheral blood mononuclear cells and BM macrophages (Kallianpur 
et al., 1994) and in zebrafish (Zhang and Rodaway, 2007) and human macrophages 
(Pulford et al., 1995). The mouse Tal1 cDNA was cloned from a BM macrophage cDNA 
library by using HLH-specific oligonucleotides as hybridization probes (Begley et al., 
1991). One aspect of studies done with myeloid leukemia cell lines is that they do not 
realistically reproduce the physiological condition and differ not only in expression 
pattern of Tal1 but also in cytokines responsible for induction of differentiation. 
Differentiation of M1 murine monocytic leukemia cells is induced by LIF or IL-6 while 
differentiation of TF-1 human bipotent cells is induced by TPA. However, differentiation 
of primary BM mononuclear precursors towards macrophage lineage initially requires a 
combination of IL-3 and M-CSF and only M-CSF at later stages of differentiation.  
In vivo deletion of Tal1 in HSCs in interferon-inducible MxI-Cre mice perturbed 
megakaryopoiesis and erythropoiesis with the loss of early progenitor cells, but did not 
appear to alter macrophage, granulocytic, mixed granulocyte/macrophage progenitor 
numbers in BM and spleen and formed colonies of similar size to controls (Hall et al., 
2003; Mikkola et al., 2003). However, loss of Tal1 in cells nullizygous for the related 
Lyl1 gene showed ten-fold reduction in myeloid colony numbers arising from LKS cells, 
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raising the possibility of genetic redundancy (Souroullas et al., 2009). Therefore, 
although the evidence suggests that Tal1 plays an active role in monocytopoiesis, 
previous studies were not definitive and could neither rule in or out Tal1 involvement in 
monocytopoiesis. 
In the present work we aimed at studying the role of this critical transcription 
factor in monocytopoiesis and investigated the molecular mechanism underlying its 
actions in this lineage. Using two different ex vivo differentiation systems, one involving 
CMPs and another involving more committed progenitor cells consisting of monoblasts 
and promonocytes, we detected Tal1 expression at all stages of monocytopoiesis and 
even in activated macrophages. Previous studies have looked at Tal1 expression in 
peripheral blood mononuclear cells and tissue macrophages (Begley et al., 1989; 
Kallianpur et al., 1994; Pulford et al., 1995), but this is the first comprehensive study of 
Tal1 mRNA and protein expression during monocytopoiesis. 
The over-expression studies showed that Tal1 has an active role in 
monocytopoiesis and confers a proliferative advantage to the cells (Fig. 8) possibly by 
inducing expression of cell surface growth factor receptors (Fig. 4). Two groups have 
investigated the effects of Tal1 over-expression in mouse BM reconstitution. One study 
could not detect any phenotype in mice over-expressing Tal1 driven by the LXSN 
retrovirus (Elwood and Begley, 1995; Elwood et al., 1998). However, another study 
showed that over-expression of Tal1 promoted myeloid repopulation, which did not 
persist beyond 10 weeks (Kunisato et al., 2004). Interestingly, transduction of TAL1 
cDNA increased the proliferation of the 32D cells via an anti-apoptotic effect and HL-60 
cells via increased DNA synthesis (Condorelli et al., 1997).  
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Microarray gene expression analysis in Tal1 over-expressing macrophages 
showed up-regulated immune response, cell signaling and proliferation pathways, (Fig. 5) 
which could be related to the overall augmentation of differentiation. Interestingly, 
expression of the DNA binding-defective mutant of Tal1 did not enhance Csf1r or Il6-r 
gene expression which suggests that direct interaction with DNA may be necessary to 
elicit these effects.  
Similar findings were also seen in M1 myeloid leukemia cells (Fig. 4), and the 
high proliferative capacity of Tal1 over-expressing cells suggest that it might be relevant 
to actions of TAL1 in T-lymphoid and, conceivably, myeloid leukemias. TAL1 
expression in human chronic myeloproliferative disorders has not been extensively 
documented and there is no evidence of chromosomal translocations or point mutations 
that affect the TAL1 locus in myeloid leukemia (Rockman et al., 1992; Delabesse et al., 
2003). However, increased TAL1 expression was detected in 7 out of 8 cases of chronic 
myeloid leukemia with myeloid blast crisis (Shimamoto et al., 1995). Moreover, de novo 
AML patients who expressed TAL1 had poor prognosis, survived for less than 1 year 
after diagnosis and showed poor complete remission (C.R.) rate (Shimamoto et al., 1995; 
Ohyashiki et al., 1996). Comparative microarray gene expression analysis of CD34+ cells 
from BM of untreated CML patients have also detected increased expression of TAL1 
and GATA2 (Diaz-Blanco et al., 2007). Finally, increased TAL1 expression has also 
been described in peripheral blood mononuclear cells in patients with myelofibrosis with 
myeloid metaplasia (Steunou et al., 2003). Future studies aimed at more detailed analysis 
of role of TAL1 in myeloproliferative disorders, particularly in chronic 
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myeloproliferative diseases may explain these findings and also elucidate pathways that 
are altered by Tal1 over-expression in myeloid cells. 
Complete loss of Tal1 gene resulted in proliferative and cell cycle defects in 
macrophage precursors, and even wild-type and heterozygous knockout cells also 
differed in their growth rates. This was most apparent at later times in culture (days 6 and 
8, Fig. 8), which suggested that more differentiated cells were most sensitive to Tal1 gene 
dose. Although earlier in vivo gene deletion studies did not reveal any defect in 
macrophage, granulocytic, or mixed granulocyte/macrophage lineage (Hall et al., 2003; 
Mikkola et al., 2003), ex vivo deletion of the Tal1 gene, as carried out here brought out 
phenotypic abnormalities, either because of the acute nature of gene loss or because 
culture conditions simulated stress monocytopoiesis. In support of the latter, SCL∆/LacZ 
mice showed a small but significant delay in the recovery of circulating monocytes after 
5-FU treatment (unpublished data, Dr. David Curtis, The Royal Melbourne Hospital, 
Australia). The cell cycle studies in SCL∆/LacZ cells showed an overall decrease in rate of 
progression through S phase and increase in G0 population while the prolonged BrdU-
labeling studies identified a higher percentage of cells that never entered cell cycle. It is 
possible that the non-cycling cells represented a population that had the highest efficiency 
in Tal1 gene deletion and exhibited the most severe phenotype.  
The proliferative defect and the particular cell cycle phases that got affected 
associated with p16(Ink4a) and p21(Cip1) gene up-regulation and were previously shown 
to be positively regulated by E proteins, while Tal1-E protein heterodimers were 
suggested to repress their transcription (Doyle et al., 1994; Hofmann and Cole, 1996; 
Prabhu et al., 1997; Park and Sun, 1998; Hansson et al., 2003; O'Neil et al., 2004). Those 
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studies have shown that E protein homodimers transactivate transcription by binding E 
box sequences in promoter regions, and Tal1-E protein heterodimer binding at the same 
sites repress this activation. Reporter assays have also shown that mutation of these E 
boxes result in complete abrogation of promoter activity and hence direct binding to these 
sequences is important to elicit gene expression. Moreover, in the Jurkat cell line in 
which Tal1-E2A transcriptional activity is low, restoration of E2A activity profoundly 
suppresses growth and increases apoptosis (Park et al., 1999). Thus, in Tal1 knockout 
MM precursor cells, abrogation of Tal1 inhibition of E protein function was likely a 
major contributor to both the up-regulation of p16(Ink4a) and p21(Cip1) expression and 
impairment in cell cycle progression and proliferation. A previous study showed that 
retroviral transduction of mutant N-ras gene (N-rasG13R) into CD34+ human cord blood 
cells resulted in up-regulation of p16(Ink4a) and p21(Cip1) expression in primitive 
CD34+ cells in a dose-dependent manner and these cells produced a higher proportion of 
myelo-monocytic progenitors (Shen et al., 2007). Therefore, this suggests that higher 
expression of p16(Ink4a) and p21(Cip1) may also contribute to the faster rate of 
differentiation seen in SCL∆/LacZ cells. 
While p16(Ink4a) transcription was inhibited by Tal1 in differentiating cells of 
this lineage, the Gata2 gene appeared to be transactivated by Tal1. A region in intron 4 of 
Gata2 was previously shown to have strong enhancer activity in endothelial and mouse 
fetal liver cells (Khandekar et al., 2007; Wozniak et al., 2007), and findings from our 
studies are compatible with it also being active in mononuclear phagocytes. Further, the 
slight acceleration of differentiation seen in Tal1 knockout cells could be explained by 
the reduced levels of Gata2. A similar phenotype was observed in JMML cells where 
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mutant Shp2-expressing hematopoietic progenitors had low Gata2 expression and 
exhibited enhanced monocytic differentiation (Yang et al., 2009). Moreover, GATA2 
expression in brown adipocyte precursors was down-regulated in a differentiation-
dependent manner and deletion of GATA2 gene resulted in enhanced differentiation (Tsai 
et al., 2005; Okitsu et al., 2007). GATA2 deleted adipocytes showed up-regulation of 
several adipocyte-specific marker genes like PPARγ, UPC-1 and PGC1α and 
mitochondrial genes like COX II, COX IV and ATP-synthase and morphologically 
showed higher intracellular lipid accumulation suggesting enhanced differentiation (Tsai 
et al., 2005). Therefore, these studies in myelo-monocytic leukemia cells and adipocytes 
suggested that Gata2 is a key regulator of this process and proper timing of Gata2 down–
regulation may be critical for differentiation. In support of this concept, maintenance of 
high-level Gata2 expression in murine bone marrow cells blocked both their 
differentiation and amplification and suggested that regulation of Gata2 expression is a 
critical event in normal hematopoiesis (Persons et al., 1999). Our data suggest that a 
similar role of Gata2 could also explain the enhanced differentiation seen in SCL∆/lacZ 
cells and could have been brought about by an earlier decline in Gata2 expression in 
these cells. 
Reduced Gata2 expression could also contribute to the cell cycle defect observed 
in SCL∆/LacZ MM precursor cells. In G1ME cells, shRNA-mediated knock down of Gata2 
expression resulted in proliferative defect brought about by delayed entry from G1 to S 
phase of the cell cycle (Huang et al., 2009). Consistent with this cell cycle defect, 
expression of several genes including E2f2 and Skp2 was reduced while Cdkn1a (p21) 
and Cdkn1b (p27) expression was increased. More interestingly, Gata2 knockdown 
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resulted in increased myeloid gene expression including Mpo, PU.1, Hhex and Cebpa 
suggesting that the cell cycle arrest could be indicative of enhanced myeloid 
differentiation (Huang et al., 2009). Our data suggest that Gata2 reduction in SCL∆/LacZ 
cells may have similarly contributed to the cell cycle delay and enhanced differentiation 
of MM precursor cells (Fig. 11A) and might have also resulted in increased Csf1r gene 
expression (Fig. 15). Interestingly, and in contrast with p16(Ink4a), Gata2 expression 
was not affected by Tal1 over-expression and was reduced only with Tal1 nullizygosity, 
reflecting, potentially, a difference in the quantitative requirement for Tal1 in genes 
activated and repressed by this transcription factor.  
Although expressed throughout the process of differentiation, DNA and protein 
interaction of Tal1 may vary depending on the target gene and that, in turn, may closely 
regulate proliferation and differentiation of MM precursors. Our gene knockout data 
suggests that TAL1 acts both as a transcriptional activator and repressor, perhaps 
depending on the interacting partners and might switch from one role to the other in a 
stage-specific manner. Studies done in our lab have clearly shown this dual activity of 
Tal1 in erythroid cells. In MEL cells, Tal1 can activate the expression of cell surface 
protein 4.2 (P4.2) by associating with a multi-protein complex (consisting of E47, 
GATA-1, LMO2, Ldb1 and SSBP2/3) that interacts with two E box-GATA motifs in the 
promoter region of P4.2 gene (Xu et al., 2003; Xu et al., 2007). Dimethyl sulfoxide 
(DMSO)-induced terminal erythroid differentiation of MEL cells results in gradual 
increase in both Tal1 and P4.2 expression. Nuclear extracts from differentiating MEL 
cells were analyzed by EMSA using a radiolabeled probe containing one of the E box-
GATA motifs in P4.2 gene promoter, and showed an increase in binding with 
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differentiation, which finally declined with terminal differentiation (Xu et al., 2003). In 
uninduced MEL cells, the SWI/SNF protein, Brg1 can also associate with the same Tal1-
containing complex at the same site to repress P4.2 expression by recruiting the mSin3A 
and HDAC2 corepressor complex (Xu et al., 2006). On induction of erythroid 
differentiation of MEL cells, Brg1 gets dissociated from the complex and switches the 
complex from a repressor to an activator of P4.2 gene expression. The Tal1-mediated 
repression of P4.2 gene expression in uninduced cells can also be augmented by co-
expression of Eto2 and Mtgr1 and both these proteins decrease with differentiation of 
MEL cells (Cai et al., 2009). 
In MM precursor cells, while p16(Ink4a) gene expression increased, Gata2 gene 
expression was found to decrease with differentiation and Tal1 knockout resulted in up-
regulation of p16(Ink4a) and down-regulation of Gata2 expression. This suggested that 
Tal1 has opposite effects in regulation of these two target genes and given that direct 
Tal1-E protein association with gene regulatory regions was detected in earlier MM 
precursor cells (day 4, Fig. 17C), Tal1 may repress p16(Ink4a) expression and activate 
Gata2 expression at this stage of differentiation (Fig. 19 i). In more mature cells (day 7, 
Fig. 17D), Tal1-E protein association at the same regulatory sites were near absent for the 
p16(Ink4a) gene and undetectable for the Gata2 gene, in spite of continued Tal1 
expression (Fig. 3A and 3E). At this stage of differentiation, p16(Ink4a) expression was 
higher than the earlier stages suggesting that other E proteins may bind these regulatory 
sites at later times or independent pathways of p16(Ink4a) regulation exist (Fig. 19 ii). 
This also suggested that Tal1 may not be required for continued repression of this gene at 
later stages of differentiation. On the other hand, Gata2 gene expression may be more 
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directly regulated by Tal1 with no binding detected in more mature cells that do not 
express Gata2 (Fig. 19 ii). Tal1-mediated active repression of p16(Ink4a) gene may have 
been relieved in SCL∆/LacZ cells where E2A homodimers or other E proteins might have 
bound the upstream E boxes and resulted in its higher expression (Fig. 19 iii). In 
SCL∆/LacZ cells, we detected a considerable decrease in Gata2 expression that could be 
explained by the absence of Tal1-E protein complex at the intron 4 enhancer region. This 
region may be specifically and selectively bound by the Tal1-E protein heterodimer and 
not by E protein homodimers and hence could not drive Gata2 expression in absence of 
Tal1. This suggested another interesting aspect in gene regulation that dictates binding 
specificity and sequence recognition by different complexes. In addition to up-regulation 
of CDK inhibitors, decline in Gata2 expression may also have added to the phenotype 
observed in SCL∆/LacZ cells. Further studies are required to identify the Tal1-interacting 
proteins and analyze the mechanism of its dual role in this lineage. Another interesting 
feature is the stability of the complexes formed, because Tal1-over expression did not 
change Gata2 expression but did result in slight decrease in p16(Ink4a) expression. 
However, the modest decline in p16(Ink4a) expression in Tal1-over expressing cells 
could  not sufficiently explain the high proliferative potential of these cells suggesting a 
different mechanism of action. Although Tal1 over-expression resulted in increased Csf1r 
mRNA expression in M1 cells and primary MM precursor cells, preliminary ChIP 
analysis for Tal1 binding at the Csf1r regulatory regions could not identify its association 
with those regions (data not shown). Therefore, the mechanism for positive regulation of 
Csf1r gene expression by Tal1 will require further studies. 
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Figure 19. Model of gene regulation by Tal1 in MM precursor cells. Schematic 
representation of Tal1 binding and target gene regulation in early precursors (i), late 
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monocyte-macrophage cells (ii), and Tal1 knockout cells (iii). Higher expression is 
denoted by gene names in bigger fonts and thicker arrows. 
 
The comparative cell proliferation studies in Tal1+/+ (wild-type) cells and Tal1+/- 
cells showed that a 50% reduction in Tal1 expression resulted in a detectable difference 
in cell numbers at later stages of the culture period (Fig. 8C). This suggested that more 
mature cells may be more sensitive to changes in Tal1 expression. Interestingly, 
p16(Ink4a) expression in SCL∆/LacZ cells was maximally up-regulated at later times in 
culture (days 6 and 8, Fig.14C) although the ChIP studies did not detect Tal1 association 
at p16(Ink4a) upstream sequences at this stage. In M1 monocytic leukemia cells, IL-6-
induced differentiation results in elevated expression of mRNA encoding dominant-
negative HLH proteins, Id1 and Id2 along with loss of Tal1-E2A DNA binding 
(Voronova and Lee, 1994). Id1 expression is also closely associated with the mouse BM 
myeloid lineage cells and is highly expressed in Mac-1+ myeloid cells and in 
mononuclear cells of blood and peritoneum (Cochrane et al., 2009). In normal human 
myeloid cells, Id2 mRNA has been detected in cultured macrophages from bone marrow 
and in mature granulocytes and monocytes from peripheral blood (Ishiguro et al., 1996). 
Preliminary studies done in transiently transfected cell lines showed that these dominant-
negative HLH proteins are critical regulators of p16(Ink4a) and p21(Cip1) gene 
expression (Prabhu et al., 1997; Alani et al., 2001). The Id proteins can inhibit cellular 
senescence through repression of p16(Ink4a) expression, and Id1-null murine embryonic 
fibroblasts (MEFs) undergo premature senescence despite normal growth profiles at early 
passages (Alani et al., 2001). Id1 over-expression can also accelerate cell growth by 
inhibiting p21 expression, probably by counteracting the action of E2A that can activate 
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p21 expression and cell cycle arrest in G1 to S phase transition (Prabhu et al., 1997). 
Future investigation into the role of Id proteins, particularly at later stages, may enable 
better understanding of this process and shed more light on function of Tal1 in this 
lineage.  
Tal1-null adult HSCs have impaired short-term repopulating ability, 
predominantly of the myeloid lineage, but no defects in long-term repopulation or self-
renewal (Curtis et al., 2004). Tal1 is essential for the formation but not the maintenance 
of adult HSCs (Mikkola et al., 2003). A possible explanation of redundant function of 
Tal1 in adult HSC is expression of the related bHLH transcription factor, Lyl1. However, 
Lyl1 cannot rescue early lethality of Tal1-null mice despite similar patterns of embryonic 
expression (Giroux et al., 2007), and enforced expression of Lyl1 in Tal1-null ES cells 
did not rescue their defective development (Porcher et al., 1999), suggesting that Lyl1 
can not compensate for Tal1 in developmental hematopoiesis. In adult hematopoiesis, 
Lyl1 is expressed in myeloid and B cell lineages as well as HSCs but is dispensable for 
hematopoietic development. Transplantation assays with Lyl1-null HSCs showed 
defective lymphoid function but did not affect myeloid repopulation, suggesting that Lyl1 
is also dispensable for adult HSCs (Capron et al., 2006). Repopulation analysis with 
HSCs from a Lyl1/Tal1-conditional double knockout mice showed a gene dose-dependent 
loss of hematopoietic progenitors due to apoptosis (Souroullas et al., 2009). A similar 
functional redundancy may also be possible in MM precursor cells. While Tal1-/-Lyl1+/+ 
CMPs showed a 3- to 4-fold upregulation in p16(Ink4a) mRNA expression, compared to 
control, almost 9- to 10-fold upregulation was noted in Tal1-/-Lyl1+/- and Tal1-/-Lyl1-/- 
CMPs (unpublished data, Dr. David Curtis, The Royal Melbourne Hospital, Australia), 
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suggesting that expression of at least this gene is regulated by both the transcription 
factors. Therefore, further studies of differentiation from Tal1-/-Lyl1-/- MM precursor cells 
may reveal more severe defects and identify a different level of gene regulation in this 
lineage. 
The DNA binding-defective mutant of Tal1 (Tal1T192P) used in the rescue analysis 
is a well-characterized mutant (Huang et al., 2000) where the single threonine to proline 
substitution renders it completely unable to interact with DNA without effecting any 
other function of Tal1. Deletion of the basic region of Tal1 (∆bTal1) has been previously 
used by other groups to study DNA-binding dependent functions of Tal1, but this mutant 
has the possibility of functioning as Id proteins which are HLH proteins lacking the basic 
region. Anyway, Tal1T192P was unable to rescue the proliferative defect in SCL∆/LacZ cells, 
which suggested that DNA-binding ability of Tal1 is critical for its function in this 
lineage. Embryos homozygous for a DNA-binding mutant of Tal1 exhibited anemia at 
the yolk sac and fetal liver stages and showed presence of immature proerythroblasts 
suggesting a complete block or delay in erythroid maturation (Kassouf et al., 2008). 
Although these embryos survived the yolk sac stage and showed earliest hematopoietic 
development and commitment, almost 80% of embryos died at E14.5 primarily due to 
defective maturation of primitive erythroid cells. Therefore, DNA-binding independent 
function of Tal1 was sufficient for hematopoietic stem/progenitor cell specification but 
was not enough for terminal erythroid maturation. Our studies showed that similar to 
erythroid maturation, DNA-binding ability of Tal1 is also required in expansion and 
differentiation of MM precursor cells. 
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Expression of Gata2 was down-regulated in SCL∆/LacZ cells and re-introduction of 
the Gata2 cDNA resulted in complete loss of cell viability within 24 hr. This suggests 
that timing of Gata2 expression may be critical in this lineage and non-redundant 
functions of Gata2 and Tal1 exist although expression of one may be regulated by the 
other. In osteoclasts, which originate from the same parental cells as macrophages, a 
sequential requirement of Tal1, Gata2, M-CSF and RANK-ligand has been demonstrated 
(Yamane et al., 2000). Gata2 is highly expressed in enriched populations of pluripotent 
HSCs (Orlic et al., 1995) and also in early erythroid cells (Leonard et al., 1993), mast 
cells (Dorfman et al., 1992), megakaryocytes (Visvader et al., 1995) and at early stages of 
CMPs differentiating towards MM lineage (Tagoh et al., 2002). Enhanced expression of 
Gata2 in BM hematopoietic progenitor cells using the same vector that we used for our 
study resulted in a 50%-80% reduction in colony formation compared to empty vector 
transduced cells (Persons et al., 1999). These cells remained viable but showed loss of 
spleen-colony forming ability and did not contribute to multilineage reconstitution of 
transplanted mice. It is possible that the loss of viability in SCL∆/LacZ cells transduced with 
Gata2 cDNA could be due to a deleterious effect of Gata2 over-expression in a Tal1-null 
background. Nevertheless, complete recovery of SCL∆/LacZ cells transduced with a Tal1 
cDNA suggested that the phenotypic consequences in SCL∆/LacZ cells were specifically 
due to Tal1 loss and not due to any indirect effects. 
From this study I propose a novel role of Tal1 in a critical branch of 
hematopoiesis. To date this is the most comprehensive study of role of Tal1 in 
monocytopoiesis that identified critical functions that are regulated by Tal1 and also 
explained the molecular mechanism behind those functions. I identified two potential 
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targets of Tal1, p16(Ink4a) and Gata2, which are extremely critical not only for 
proliferation, cell cycle control and differentiation but also in macrophage function. 
Previous studies have suggested that Tal1-E protein binding at upstream E box sequences 
regulate expression of CDK inhibitors but none of these studies demonstrate endogenous 
binding of these factors at regulatory E box motifs. We could detect direct association of 
Tal1 and E protein at p16(Ink4a) upstream regulatory sites and also proposed a possible 
mechanism of regulation at different stages of monocytopoiesis in primary BM cells. 
Expression of Gata2 was also shown to be regulated by the intron 4 enhancer in MM 
precursors similar to previous findings in embryonic endothelial and hematopoietic cells. 
Therefore, our study probably adds another level of control in this cell lineage and 
explains how the regulators are being regulated. Although we concentrated on the 
physiological role of Tal1 in growth and differentiation of monocytes into macrophages, 
further study to investigate its role in macrophage lineage may also be interesting. In vivo 
macrophage depletion by injection with liposomal-encapsulated clodronate (LIP-CLOD) 
induced megakaryocytic and thrombopoietic activities (Alves-Rosa et al., 2003), reduced 
BFU-E numbers and circulating reticulocytes (Giuliani et al., 2001) and produced 
erythroid abnormalities (Giuliani et al., 2005; Lisa Giuliani et al., 2007). Whether the 
function of Tal1 in macrophages is related to formation of erythroid blood islands in BM 
warrants further investigation and might explain the in vivo role of Tal1 in this lineage. 
Taken together, our studies elucidate a novel physiological role of Tal1 that may 
also be involved in hematopoietic disorders. It also suggests molecular mechanisms of 
the function of this transcription factor and identifies novel target genes and suggests new 
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cellular and biological functions that may be regulated by this important bHLH 
transcription factor. 
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